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″Upon this gifted age rains from the sky a meteoric shower
of facts... they lie unquestioned, uncombined.
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there exists no loom to weave it into fabric″.
(Edria St. Vincent Millay)
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1 Abstract
1.1 General Introduction
Pharmaceutical drug development is a long and expensive process. Lacking a priori
knowledge about which compound might serve as a drug in a certain disease indication,
this process traditionally contains a series of distinct steps, including an initial screening
assay of low molecular weight compounds against the target enzyme, followed by a
selection of a candidate lead compound from the initially identified hits. Early selection of
promising molecules can dramatically improve this process, but so far, there are only few
well defined criteria to perform this selection.
The shortcoming of traditional drug discovery as well as the appeal of a more
deterministic approach to combat diseases has led to the concept of "Rational Drug
Design". Detailed information about the disease or infectious process is a requirement for
drug design. Hereby, the first necessary step is the identification of a molecular target
critical to a disease process or an infectious pathogen. An additional important prerequisite
of drug design is the determination of the precise three-dimensional molecular structure of
the target by X-ray crystallography, ideally complexed with substrate analogues or
(natural) inhibitors. This structure then serves as a blueprint for the design of a lead
compound. Selected compounds are modeled for their fit in the active site of the target,
considering both steric aspects (i.e., geometric shape complementarity) and functional
group interactions, such as hydrogen bonding and hydrophobic interactions. The initial
design phase is followed by an iterative refinement procedure which includes the synthesis
of the lead compound, quantitative measurements of its ability to interact with the target,
and X-ray crystallographic analysis of the compound-target complex. This analysis reveals
important empirical information on how the compound actually binds to the target and the
nature and extent of changes induced in the target by the binding. These data, in turn,
suggest ways to improve the lead compounds binding affinity. The refined lead compound
is then synthesized and complexed with the target, and further refined in a reiterative
process. Once a sufficiently potent compound has been designed and optimized, its
activity is evaluated in a biological system to establish the function in a physiological
environment. This process continues until a designed compound exhibits the desired
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properties. The compound is then evaluated in an experimental disease model to prove its
status as an experimental drug. The experimental drug candidate is then ready for
conventional drug development in a clinical trial.
The drug discovery approach by which synthetic compounds are designed from detailed
structural knowledge of the active sites of protein targets associated with particular
diseases is called "Structure-Based Drug Design".1-6 The following figure emphasizes the
cyclic and multidisciplinary aspects of this type of drug design.
Figure 1.1  The cycle of structure-based drug design.
In fact, this method is limited to the availability of a high-resolution target structure with
its substrate recognition sites defined at atomic detail. Only with this information
"Structure-Based" or "Rational Drug Discovery" will be feasible.
1.2 Summary of the Results
In the last decade the zinc-containing matrix metalloproteinases (MMPs) have become
attractive targets for structure-based drug design because of their implication in a variety
of diseases in which the destruction of connective tissue is an important pathological
event. To date the main focus of the therapeutic applications of MMP inhibitors (MMPIs)
has been in the areas of cancer and arthritis. An appreciation for the potential role of
MMPs in other pathological conditions is ever expanding. The design of MMPIs has been
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primarily based upon imitation of the binding scheme of natural protein substrates such as
collagen to the MMPs. Peptidomimetics, pseudopeptides or non-peptide inhibitors which
incorporate a zinc-binding group and side chains which interact with the enzyme subsites
form the common structural scaffold. The most ubiquitous type of inhibitor is designed to
bind to the primed substrate recognition sites ("right-hand side") of the enzyme using a
hydroxamic acid as the zinc chelator. Because of the biologically labile nature of
hydroxamates, the low oral bioavailability, and poor duration of action exhibited by most
peptide-based compounds, two important aims of the present thesis to the design,
synthesis, and biological evaluation of inhibitors of matrix metalloproteinases are
highlighted: 1. the invention of alternatives to hydroxamic acid zinc-chelators, and 2. the
construction of non-peptide scaffolds.
In this thesis a new generation of heterocyclic non-peptide matrix metalloproteinase
inhibitors derived from a 6H-1,3,4-thiadiazine scaffold was discovered. A screening effort
identified some chiral N-alkyl-(6-methyl-5-phenyl-6H-1,3,4-thiadiazine-2-yl)-amines
which are weak inhibitors (Ki > 40 µM) of the catalytic domain of human neutrophil
collagenase (cdMMP-8). Further chemical modifications including the removal of the
6-methyl group resulted in novel 5-substituted 6H-1,3,4-thiadiazine-2-amides which show
promising potency against MMPs. The breakthrough of this compound series was
initialized by the incorporation of a N-sulfonylated amino acid as the carboxylic acid
component to improve right-hand side binding affinity. The new compounds were tested
against eight different matrix metalloproteinases, MMP-1, cdMMP-2, cdMMP-8, MMP-9,
cdMMP-12, cdMMP-13, cdMMP-14, and the ectodomain of MMP-14. An in-depth
examination of structure-activity relationships (SARs) on modifications of the position 5
substituent, on modifications of the sulfonamide residue, and on variations of the α-carbon
substituents produced the selective inhibitor (2R)-N-[5-(4-bromophenyl)-6H-1,3,4-
thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]propanamide with high affinity for MMP-9
(Ki = 40 nM) and (2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(2-thienyl-
sulfonyl)amino]propanamide with high affinity for cdMMP-8 (Ki = 60 nM).
The X-ray crystallographic structure determined at 2.7 Å resolution for cdMMP-8 co-
crystallized with N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide
gave detailed design information on key binding interactions for thiadiazine-based MMP
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inhibitors. In addition the crystal structure of uncomplexed N-allyl-5-(4-chlorophenyl)-6H-
1,3,4-thiadiazin-2-amine hydrobromide was determined and compared with the complexed
structure. This comparison and the calculation of ring puckering parameters for both
structures reveal a preferential screw-boat conformation of the thiadiazine system when
complexed to cdMMP-8. The coordination to the catalytic zinc cation is surprisingly
mediated via the exocyclic nitrogen of the thiadiazine moiety, while the ring nitrogens are
involved in specific hydrogen bonds with the backbone of cdMMP-8. These results
indicate that 6H-1,3,4-thiadiazine-based MMPIs interact with both the primed and the
unprimed side of the MMP.
To explore the structures of 6H-1,3,4-thiadiazine-2-amide-based MMPIs a method to
crystallize these compounds was developed within this thesis. Using X-ray crystallography
an amido-imino tautomerism (prototropic shift) shown by different bond lengths within
the 6H-1,3,4-thiadiazine moiety was elucidated for this compound series. Therefore, the
endocyclic N3 of the 6H-1,3,4-thiadiazine core fragment acts either as a hydrogen-bond
acceptor or a hydrogen-bond donor depending on the state of the tautomeric equilibrium.
Since suitable crystals of the cdMMP-8/(2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-
yl]-2-[(2-thienylsulfonyl)amino]propanamide complex could not be obtained for X-ray
studies, cdMMP-8/inhibitor docking experiments were performed using the program
FlexX. The crystal structure of uncomplexed (2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-
thiadiazin-2-yl]-2-[(2-thienylsulfonyl)amino]propanamide was determined at 0.84 Å
resolution and shows two molecules per asymmetric unit. Within the molecules different
ring conformations of the thiadiazine system occur. The atom coordinates of these two
structures in combination with coordinates from the complexed reference inhibitor N-allyl-
5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine were used to perform the virtual docking
to cdMMP-8. The comparison of the minimized energies and the best rms-values (best rms
means closest to reference structure) for the binding models reveal that the 2-thienyl
residue does not fit into the S1' pocket but is positioned on the normal vector to the
catalytic zinc(II)-ion at 5.1 Å distance. These results suggest that cation-aromatic
interations may play a role in stabilizing the enzyme/inhibitor adduct.
To test the anti-tumor activity of the novel thiadiazine-based MMPIs an in vitro cell assay
with the mamma carcinoma cell-line MDA-231 BAG was performed. The inhibitor
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(2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]propan-
amide was assayed using a potent MMP inhibitor as a reference. It was found that both the
thiadiazine-based inhibitor and the reference inhibitor can reduce the gelatinolytic activity
of the cell-line by about 20 percent. As an additional benefit, the thiadiazine-based
inhibitor displayed this activity at about 50 percent lower concentration compared to the
reference inhibitor. Since the reference inhibitor was tested in a synergic mouse lymphoma
model with great success, thiadiazine-based MMPIs are now attractive candidates for
in vivo tumor models.
In summary, a complete drug design work was performed with this thesis. The discovery
of 6H-1,3,4-thiadiazine-based MMPIs may be regarded as a breakthrough for continued
development of inhibitors of matrix metalloproteinases as drugs.
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2 Theory
2.1 Metzincins
Proteinases can be subdivided into four major classes: serine-, cysteine-, aspartic- and
metalloproteinases due to their residue crucial in catalysis. The majority of zinc containing
metalloproteinases exhibit a characteristic HEXXH consensus sequence integrated into an
"active-site helix". The two histidine residues serve as zinc ligands, and the glutamic acid
residue polarizes a water molecule involved in nucleophilic attack at the scissile peptide
bond. These features were first examined in the structure of the gluzincin thermolysin.7
The metzincins, classified by Bode et al., have an extended zinc binding consensus
sequence HEXXHXXGXXH, where the third histidine acts as the third zinc ligand instead
of the more distant glutamic acid in thermolysin.8 In addition this superfamily has a
methionine-containing turn the conformation of which is strictly conserved (the Met-turn).
unknown
 Proteinases
Serine Proteinases Cysteine Proteinases Aspartic Proteinases Metallo Proteinases
HXXEH
   HXXE
HXH
binuclear unknown
Gluzincins
HEXXH
Serralysins Matrixins   Astacins Adamalysins
 HEXXHXXGXXH
HEXXH
ZincinsInsulinase family Carboxy-
peptidase
family
Metzincins
DD-Carboxy-
 peptidase
Figure 2.1  Families of proteinases. The families of the zinc metalloproteinases and their inter-
relationship based on the sequence around the zinc-binding residues are shown. Italicised bold
letters represent the consensus sequence.
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The metzincin superfamily consists of four subfamilies: the astacins, the serralysins, the
snake venom adamalysins (ADAMs: A Disintegrin And Metalloproteinase), and the
matrix metalloproteinases (matrixins).
2.2 Matrix Metalloproteinases
The matrix metalloproteinases (MMPs, matrixins) form a subfamily of the metzincins and
are structurally and functionally related zinc- and calcium-dependent endopeptidases.
Figure 2.2  Domain structure of matrix metalloproteinases. IL-R = interleukin-like receptor.
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The proteolytic activity is directed against most constituents of the extracellular matrix
(ECM), like proteoglycans, fibronectin, laminin, and interstitial collagens.9,10 At present
time, 20 members of the human MMP family have been characterized. Based on their
structure and substrate specificity, MMPs are divided into subgroups of collagenases,
stromelysins, stromelysin-like MMPs, gelatinases, membrane-type MMPs (MT-MMPs),
and other MMPs.11 They all share similar domain structures, which include four major
regions: an N-terminal leader sequence involved in secretion, a prodomain that inhibits the
enzymatic activity, a catalytic domain, and a hemopexin domain which determines the
substrate specificity of MMPs and, in the case of MMP-2, MMP-9 and MMP-13, mediates
interactions with their endogenous inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs).12,13 The hemopexin domain is absent in matrilysin (MMP-7) and MMP-26. In
addition, gelatinases A and B (MMP-2 and MMP-9) contain three repeats of the
fibronectin-type II domain inserted in the catalytic domain. MT-MMPs contain a
transmembrane domain, which anchors these enzymes to the cell surface. MT-MMPs,
MMP-11, and MMP-23 also contain a furin cleavage site between the pro-peptide and the
catalytic domain, suggesting that these pro-enzymes are activated intracellularly by furin
or related enzymes.
Figure 2.3  Cell surface-associated activation cascades for MMPs.
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All MT-MMPs can activate pro-MMP-2. It has been shown that in the process of pro-
MMP-2 activation, MT1-MMP is proteolytically activated before it binds the
pro-MMP-2/TIMP-2 complex at the cell surface.14 MT1- and MT2-MMP can also activate
pro-MMP-13. This extracellular activation of pro-MMPs is probably limited to the
pericellular environment where cell-associated proteinase activities can function in an
inhibitor-depleted environment. However, the key initiators of the MMP activation
cascades are MT1-MMP and MT2-MMP, which are activated intracellularly, and
urokinase-like plasminogen activator (uPA), which is bound to its cell surface receptor
(uPAR) (Figure 2.3).15 At the transcriptional level MMPs are regulated by cytokines and
growth factors which stimulate the synthesis and secretion of pro-MMPs as well as of
TIMPs. Functionally active forms of pro-MMPs are released via the "cysteine switch"
mechanism, whereby the cysteine containing pro-domain is dislocated from the essential
zinc of the catalytic module through the proteolytic cleavage of loops necessary for pro-
peptide stability.16 Activated MMPs are thought to play an important role in the
physiological degradation of ECM components, e.g. during tissue repair, tissue
morphogenesis and angiogenesis.17 In addition, they play a role in pathological conditions
characterized by excessive degradation of ECM, such as osteoarthritis, rheumatoid
arthritis, periodontal disease, multiple sclerosis, or tumor metastasis.18-22 Therapeutic
interventions are possible at one or more biochemical sites of the MMP activation
cascades, but direct inhibition of enzyme action by synthetic agents that bind to the
catalytic site is a particularly compelling and validated objective.
2.3 Synthetic Matrixin Inhibitors
Two approaches to the identification of matrixin inhibitors have been followed: substrate-
based design of pseudopeptide derivatives and random screening of compound libraries
and natural products. The design of early matrixin inhibitors was based on the scissile site
sequence of peptide substrates. This is the sequence around the glycine-isoleucine and
glycine-leucine cleavage sites in the collagen molecules that are hydrolysed by collagenase
(Figure 2.4).
Chapter 2   Theory 10
Figure 2.4  Design of matrix metalloproteinase inhibitors based on the cleavage site of collagen.
The key to obtain potent enzyme inhibition has been the incorporation of a zinc-binding
group (ZBG) into peptide analogues of the substrate sequence positioned either on the
left-hand side (LHS) or the right-hand side (RHS), or in between both sides of the
cleavage site. At an early stage, it was found that RHS inhibitors featuring a hydroxamic
acid ZBG, are particularly potent in terms of their in vitro activity.23 Considerable insight
into MMP/ligand interactions has been obtained from the study of inhibitor structure-
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activity relationships (SARs).24,25 The use of high-resolution X-ray crystallography and
NMR spectroscopy in the elucidation of structures is providing new paradigms for the
design of inhibitors in general and selective inhibitors in particular.26-33 From X-ray
crystallographic analysis and homology modeling, the MMPs can be divided into two
structural classes dependent on the depth of the S1' pocket. This selectivity pocket is
relatively deep for the majority of the enzymes like gelatinase A (MMP-2), stomelysin-1
(MMP-3) or collagenase-3 (MMP-13), but for certain enzymes like human fibroblast
collagenase (MMP-1) or matrilysin (MMP-7) it is partially or completely occluded due to
an increase in size of the side-chain of amino acid residues that form the pocket.34
Consequently, the main type of selectivity that has been obtained favors the inhibition of
the deep pocket enzymes over the short pocket enzymes. This is achieved by the
incorporation of an extended P1' group, whereas the presence of smaller P1' groups
generally leads to broad-spectrum inhibition. This selectivity filter is realised in several
MMPI structures which are still under development, including succinyl hydroxamates,
sulfonamide hydroxamates and non-hydroxamates.35 This classification for MMPIs further
includes the so-called first generation MMPIs, which are pseudopeptide derivatives based
on the structure of the collagen molecule at the site of initial cleavage by interstitial
collagenase, and the next generation MMPIs, which are non-peptide compounds with
selective inhibitory activity against individual MMPs.
2.3.1 Zinc−Binding Groups
The selection of suitable ZBGs has been the subject of intense interest within the research
groups. Several different zinc chelators like hydroxamate, carboxylate, sulfhydryl,
sulfodiimide and derivatives of phosphoric acid have been identified.36-41  Pseudopeptides,
based on phosphorus ZBGs, represented a first interesting inhibitor design alternative. In
contrast to peptidic inhibitors containing a thiol or a carboxylate function, these inhibitors
act as good mimics of the substrate in the transition state if the zinc-binding function is
placed internal at the inhibitor backbone. In this regard, phosphinic chemistry allows the
development of transition-state analogues capable to interact with both the primed and
unprimed side of the active site cleft. This property can be exploited to optimize inhibitor
selectivity.42,43
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Figure 2.5  Different zinc chelators used in MMP inhibitor templates.
However, the hydroxamates have proved to be the most useful ones and the majority of
inhibitors currently under clinical investigation contain this group. The hydroxamate acts
as a bidentate ligand with each oxygen at an optimum distance (1.9 – 2.3 Å) from the
active site zinc(II)-ion. The position of the hydroxamate nitrogen suggests that it is
protonated and forms a hydrogen bond with a carbonyl oxygen of the enzyme backbone.44
As shown in Figure 2.6, the hydroxamic acid unit with at least 4-point attachments
behaves like a molecular magnet, the significance of which becomes clear as one converts
this group to its corresponding carboxylic acid with a concomitant 100 to 1000 fold loss in
binding affinity. The remaining residues (R1, R2 etc.) play a significant role in filling
specific pockets, endowing the individual inhibitors with unique potency and selectivity.45
Figure 2.6  Overview of key enzyme/inhibitor interactions of succinyl RHS-hydroxamates
(active site of stromelysin-1 is shown).
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2.3.2 First Generation MMPIs
Representative examples of this series of MMPIs featuring a succinyl scaffold are the
broad-spectrum hydroxamates batimastat (BB-94) and marimastat (BB-2516) developed at
British Biotech.46
Figure 2.7  Structures of first generation MMPIs reported to be evaluated in clinical trials.
Batimastat was the first compound to enter clinical investigation because of its ability to
inhibit primary tumor growth, metastatic spread, and secondary tumor growth in vivo.47
Despite the effectiveness of batimastat the development of this agent was discontinued
because of its low oral bioavailability. The compound's utility is further limited by poor
water solubility.48 Latest data seem to indicate that batimastat as a hydroxamate-type
MMPI promotes liver metastasis.49 Structural modification of batimastat resulted in the
synthesis of marimastat, which retains the inhibitory activity of its predecessor but shows a
species dependent oral bioavailability. It is a potent inhibitor of MMPs, exhibiting
Ki -values in the nanomolar range against MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9 and MMP-14. Using animal cancer models, marimastat has been observed to
inhibit tumor growth and metastasis.50,51 Unfortunately, the development of marimastat
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was problematic in that, as an anti-tumor drug, it was not expected to induce the reduction
in tumor size associated with conventional cytotoxic drugs.52
Batimastat and marimastat are examples of RHS inhibitors with the ZBG on the left end,
which has prompted several research groups to establish SAR considerations for this type
of MMPIs. Figure 2.8 shows the summary of SARs, which apply to most MMPIs with a
succinyl scaffold.53
Figure 2.8  Summary of structure-activity relationships for right-hand side MMPIs.
2.3.3 Next Generation MMPIs
In order to develop non-peptidic MMPIs with a selective inhibitory profile, a new concept
of inhibitor design has been followed. The discovery and disclosure of CGS-27023A, a
small non-peptide MMPI at Ciba-Geigy in the mid-1990's represented a major advance
with this concept.54,55 The obvious potential of a small molecule inhibitor to overcome the
pharmacokinetic problems associated with peptides, such as poor absorption and
metabolic lability, attracted the interest of a large number of research groups and has led to
several promising compounds based on the sulfonylamino hydroxamic acid scaffold.
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Figure 2.9  Structure of CGS-27023A, a next generation MMPI.
Related compounds have also been independently identified by other research groups
through "High-Throughput-Screening" (HTS). In general, these inhibitors have a ZBG like
hydroxamic acid, carboxylic acid or thiol and a group capable of acting as a hydrogen
bond acceptor (HBA) like sulfone, ketone or ether spaced apart by two atoms.
Figure 2.10  Development of non-peptide MMPIs.
The HBA group is typically substituted with an aryl group (AG) which interacts with the
S1' site. In general, the size of this substituent determines selectivity: with monophenyl
groups usually resulting in broad-spectrum inhibition and with larger biaryls, which are
often linked through an oxygen, providing selective inhibitory activity to MMPs with a
deep S1' pocket.56  Exceptions from this rule exist, however. Since the R2 residue usually
projects towards the open solvent pocket, a short tether can be attached between R1 and R2
to form a small ring.
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Representative examples of this series of MMPIs are the biphenylbutyric acid derivative
BAY-129566 developed at Bayer and the heterocyclic sulfonamide Prinomastat
(AG-3340) developed at Agouron (Figure 2.11). The clinical candidate BAY-129566 was
derived from a series of related γ-keto carboxylic acids. As with the sulfonamide
CGS-27023A, the key to the discovery of this series was HTS, which identified a fenbufen
derivative as a micromolar MMP-3 inhibitor. The examination of the SAR of the
α-position and of the terminal phenyl substitution of the fenbufen derivative led to
BAY-129566.
Figure 2.11  Next generation MMPIs reported to be evaluated in clinical trials.
It is the only MMPI under clinical investigation that is a carboxylic acid. In preclinical
studies, the inhibitory activities in both in vitro and in vivo models of matrix invasion,
malignant angiogenesis and tumor growth were notable.57 Preclinical pharmacologic
studies in mice, rats, guinea pigs and dogs indicated that the compound is highly
bioavailable after oral administration. It is further notable, that the recommended dose for
subsequent disease-directed studies is 800 mg twice daily to achieve biologically relevant
pharmacologic profiles. Unfortunately, the development of BAY-129566 was abandoned
because no positive effects could be revealed in humans in a clinical phase-III trial.58
The discovery of CGS-27023A has paved the way to design more potent non-peptide
inhibitors of MMP-3, the gelatinases A and B (MMP-2, MMP-9) and collagenase-3
Chapter 2   Theory 17
(MMP-13). Agouron has disclosed a series of related aryloxyphenylsulfonyl compounds
that display selectivity for certain MMPs.59 Ultimately, the choice of Prinomastat
(AG-3340) over other candidates was based on pharmacokinetic properties and the
efficacy of this compound in animal models of cancer.60,61 It is a selective inhibitor, which
targets inhibition of gelatinase A and B, collagenase-3, and stromelysin-1 exhibiting
Ki -values in the picomolar range. Clinical studies with this promising compound are still
under way.
2.3.4 Other Inhibitors
Irreversible MMP-inhibitors62, selective MMP-3 inhibitors based on peptide-linked
5-amino-1,3,4-thiadiazole-2-thiones63, non-peptide inhibitors of MMP-8 and bacterial
collagenases, based on tetracyclines, anthraquinones and aranciamycin64-67, are also
reported in the literature. However, the inhibitory activities of these compounds are
generally very weak in comparison to many of the inhibitors described. Thus, these
compounds may provide leads for drug design work.
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3 Aims of the Study
Matrix metalloproteinases are involved in extracellular matrix remodeling. Under normal
physiological conditions, their proteolytic activities are controlled by maintaining a
delicate balance of pro-MMP synthesis, activation and their inhibition by endogenous
inhibitors. Under pathological conditions, this balance is altered, often resulting in an
abnormally high proteolytic activity: in arthritis, there is uncontrolled destruction of
cartilage; in cancer, increased matrix turnover is thought to promote tumor cell invasion.68
Modulation of the MMP regulation is possible at several biochemical levels such as gene
expression or zymogen activation, but direct inhibition of enzyme action provides a
particularly attractive target for therapeutic intervention. Thus, the design and synthesis of
inhibitors of matrix metalloproteinases continues to be a prominent area of pharmaceutical
research. Both peptide- and non-peptide-based inhibitors are in clinical studies for various
indications. One key issue in the clinical development of MMPIs relates to whether the
development of broad-spectrum inhibitors, active against a range of different enzymes, or
of selective inhibitors, targeted against a particular subset of the MMPs, represents the
optimal strategy. However, since their inception during the eighties, MMPIs have
undergone several cycles of metamorphosis. Within promising compound classes the
hydroxamate moiety plays a decisive role in achieving inhibitor potency. Clinical data
suggested that the biologically labile nature of hydroxamates and the low oral
bioavailability and poor duration of action exhibited by most peptide-based compounds are
responsible for the failure of many compounds in clinical trials.
The aims of the present study were:
• the design, synthesis, and biological evaluation of inhibitors of matrix
metalloproteinases.
• the invention of alternatives to hydroxamic acid zinc-chelators.
• the construction of non-peptide scaffolds.
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4 Results and Discussion
4.1 Identification of Lead−Structures
In recent years, interest in thiadiazines has increased due to the high biological activity and
broad-spectrum action of their derivatives.69 Many thiadiazines have been discovered with
possible applications in medical practice as sedatives, antianxiety agents, antiasthmatic
agents, anticonvulsants, myorelaxants, coronary vasodilators, and spasmolytics. Many
thiadiazines have cardiovascular activity.
From the six theoretically possible thiadiazines, the 1,3,4-isomer has been the most
thoroughly investigated one.
Figure 4.1  The isomeric ring structures of thiadiazines. For the 1,3,4-isomer the tautomeric
6H-1,3,4, 4H-1,3,4 and 2H-1,3,4 forms are shown.
In addition, 1,3,4-thiadiazines may exist in three different tautomeric forms. Spectroscopic
investigations suggest that the 6H-form is preferred. The 4H-form represents a potentially
anti-aromatic 8π-system which can be transformed by valence isomerization to a
thiahomopyrazole and by subsequent extrusion of sulfur to a pyrazole.70
Substituted 6H-1,3,4-thiadiazines are reported to be inhibitors of lipoxygenase,
phosphodiesterase, and of the angiotensin-converting enzyme (ACE).71-73 The value of
6H-1,3,4-thiadiazine derivatives as MMP inhibitors has, however, not hitherto been
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recognized. To explore this issue further a series of chiral 6-methyl-6H-1,3,4-
thiadiazines74-77 gratefully received from the institute of chemistry and biochemistry at the
University of Greifswald, was tested using the catalytic domain of human neutrophil
collagenase (cdMMP-8) as the screening enzyme (see the experimental section for
complete assay protocol). From this analysis, a small number of compounds 1-3 were
determined to be competitive inhibitors with weak (Ki > 40 µM) inhibitory activity.
Figure 4.2  Thiadiazine screening leads.
The lead structures consist of a 6-methyl-6H-1,3,4-thiadiazine scaffold, a phenyl
substituent in position 5, and an N-alkyl substituent in position 2. At this design stage, the
binding mode of compounds 1-3 to cdMMP-8 was still unclear. With the aid of the
visualization program InsightII (MSI, Germany) and the three-dimensional structure of
recombinant cdMMP-8 complexed with the hydroxamate inhibitor Pro-Leu-Gly-NHOH,
the leads were manually docked into the active site of the enzyme. Several orientations of
the energy minimized lead-structures were superimposed upon the reference hydroxamate
inhibitor structure to map possible binding distances of the 6H-1,3,4-thiadiazine core
structure to the catalyic zinc(II)-ion. These results were compared with energy minimized
structures of 6-methyl-6H-1,3,4-thiadiazine compounds, which showed no inhibitory
activity against cdMMP-8. From these trials, the following theoretical binding mode was
postulated: the phenyl substituent fits into enzyme pockets on the unprimed side, while the
6-methyl-6H-1,3,4-thiadiazine scaffold coordinates to the catalytic zinc(II)-ion and the
N-alkyl residue is directed towards the S1' pocket.
Chapter 4   Results and Discussion 21
4.2 Modifications of the Lead−Structures
In order to prove the binding statement and to get a lead structure for further
modifications, the alkyl groups at position 2 and 6 of the 6H-1,3,4-thiadiazine scaffold
were removed. The resulting 2-amino-5-phenyl-6H-1,3,4-thiadiazine is a good starting
lead to test the concept of amide-linked 5-substituted 6H-1,3,4-thiadiazine derivatives. As
a first trial the dihydroorotic acid derivative 11 was synthesized.
Figure 4.3  The chemical structure of (4S)-2,6-dioxo-N-(5-phenyl-6H-1,3,4-thiadiazin-2-
yl)hexahydro-4-pyrimidinecarboxamide 11.
Ultimately, the choice of (S)-(+)-dihydroorotic acid over other carboxylic acids was based
on the hydrogen bonding interactions, which this heterocycle may provide with the
backbone of cdMMP-8. Surprisingly, this compound showed promising potency of
Ki = 6.2 µM against cdMMP-8 and Ki  = 1.2 µM against MMP-9.
As previously outlined, the most active compounds from the class of non-peptide MMP
inhibitors possess an arylsulfonyl group, occupying the specificity S1' pocket of the
enzyme. It was also shown that the –SO2− moiety of these inhibitors is involved in several
strong hydrogen bonds with amino acid residues from the active site cleft, which
considerably stabilize the enzyme-inhibitor adduct.78 Assuming that the phenyl ring of 11
occupies the unprimed site of cdMMP-8 or MMP-9, the next effort was the preparation of
5-substituted 6H-1,3,4-thiadiazine-2-amines acylated with a N-arylsulfonyl substituted
amino acid derivative to improve primed side binding affinity.
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4.3 Chemistry
The 1,3,4-thiadiazine system was first reported by P. K. Bose, employing a reaction of
α−bromoacetophenone with thiosemicarbazide.79 Depending on whether condensation
occurs at the N1, N2, or N4 of the thiosemicarbazide, three different sulfur-containing
heterocyclic rings are expected after ring closure: the 6H-1,3,4-thiadiazines (I), the
2-substituted imino-2,3-dihydrothiazol-3-amines (II), and the 3-substituted 2-hydrazono-
2,3-dihydrothiazoles (III).
Scheme 1.
Which isomer is formed exclusively or preferentially, decisively depends on the respective
H+-ion concentration, the polarity of the solvent, the reaction temperature and on the
substituents R1 and R2. The synthesis of the 6H-1,3,4-thiadiazine-based MMPIs was
accomplished using two methods. In the first method, a substituted α-bromo-keto
compound 4 was allowed to react with thiosemicarbazide in ethanol at 0°C (Scheme 2).
The resulting linear intermediate 5 was isolated and then ring-closed by heating this
compound in an ethanol/H2O/HBr mixture to afford preferentially the 5-substituted
6H-1,3,4-thiadiazine-2-amines 6(c-i) as their hydrobromide salts in good isolated yields.80
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Scheme 2.  Method Aa
a Reagents and conditions: (i) thiosemicarbazide; EtOH; 0 to 20°C; (ii) EtOH, 48% aq. HBr,
reflux; (iii) a) K2CO3/H2O, R4-SO2Cl, reflux, b) conc. HCl; (iv) EDC, HOBt, NMM, DMF, 5°C.
To obtain the desired sulfonamides 8(a-g) a L- or D-configurated amino acid 7 was heated
with the appropriate sulfonylchloride in an aqueous potassium carbonate solution.
Acylation of the 5-substituted 6H-1,3,4-thiadiazine-2-amine hydrohalides 6(a-k) (Table 1)
with the carboxylic group of the sulfonamides 8(a-g) (Table 2) was mediated by a mixture
of N-ethyl-N'-(3-dimethyl-aminopropyl)-carbodiimide hydrochloride (EDC), 1-hydroxy-
benzotriazole (HOBt) and 4-methylmorpholine (NMM) in DMF at 5°C. The compounds
with the general structure 9 were obtained as white or yellow solids which could be
crystallized from methanol/acetonitrile mixtures as described in the experimental section.
The latter step was also used to synthesize compound 11 from (S)-(+)-dihydro-orotic acid
and compound 6a.
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Table 1.  Synthesized 5-Substituted 6H-1,3,4-Thiadiazine-2-Amine Hydrohalides 6(a-k).
compd R1 formula mp (°C)
6a Ph C9H10ClN3S 206
6b 4-F-Ph C9H9ClFN3S 231
6c 4-Cl-Ph C9H9BrClN3S 227
6d 4-Br-Ph C9H9Br2N3S 218
6e 4-O2N-Ph C9H9BrN4O2S 228
6f 4-NC-Ph C10H9BrN4S 248
6g 4-F3C-Ph C10H9BrF3N3S 224
6h 4-H3CO-Ph C10H12BrN3OS 185
6i 4-H3C-Ph C10H12BrN3S 220
6j 1-adamantyl C13H20BrN3S 251
6k 5-Cl-2-thienyl C7H7BrClN3S2 249
Table 2.  Synthesized N-Sulfonylated Amino Acids 8(a-g).
compd R2 R3 R4 formula mp (°C)
8a(S) H CH3 Ph C9H11NO4S 123-125
8b(R) CH3 H Ph C9H11NO4S 124-126
8c(S) H CH3 2-thienyl C7H9NO4S2 85-87
8d(S) H CH3 CH2-Ph C10H13NO4S 125-127
8e(S) H CH(CH3)2 Ph C11H15NO4S 149
8f(R) CH(CH3)2 H Ph C11H15NO4S 148-149
8g CH3 CH3 Ph C10H13NO4S 146-147
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In the second method, the thiadiazine ring was prepared in one step from the substituted
α-halogeno-keto compound and thiosemicarbazide hydrochloride or thiosemicarbazide
hydrobromide.
Scheme 3.  Method Ba
a Reagents and conditions: (i) thiosemicarbazide hydrohalide; MeOH; reflux.
Compound 10 was slowly heated with the corresponding thiosemicarbazide hydrohalide in
methanol to produce the 5-substituted 6H-1,3,4-thiadiazine-2-amine hydrohalides
6(a,b,j,k) as crystalline precipitates which could be purified by recrystallization from an
appropriate solvent as described in the experimental section. Only with this method the
novel compound 5-(5-chloro-2-thienyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide could
be obtained in an acceptable yield. The remaining transformation leading to compounds
with the general structure 9 was performed as illustrated in Scheme 2.
4.4 Structure−Activity Relationship (SAR) Analysis
All compounds were tested in vitro for the inhibition of PMNL-gelatinase (MMP-9) and
the recombinant catalytic domains of human neutrophil collagenase (cdMMP-8), human
gelatinase A (cdMMP-2), macrophage elastase (cdMMP-12), collagenase-3 (cdMMP-13),
and membrane-type-1 MMP (cdMMP-14). Selected compounds have also been tested for
the inhibition of collagenase-1 (MMP-1) and the ectodomain of membrane-type-1 MMP
(MMP-14). The compound class generally inhibits cdMMP-2, cdMMP-8, MMP-9, and
cdMMP-14 selectively in the nanomolar range. Depending on functional group
manipulations within the compound series the inhibition of these MMPs showed great
variability. On the other hand, the inhibition of MMP-1 and cdMMP-12 was less potent
relative to the other enzymes and demonstrated very few variations in potency as
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functional groups were altered. Surprisingly, the inhibition of cdMMP-13, in general,
occurs in the micromolar to submicromolar range within the tested 6H-1,3,4-thiadiazine
series (Tables 3 to 7). The promising concept of this novel class of MMPIs led to the
establishment of SAR which apply to most of the 6H-1,3,4-thiadiazines described in this
thesis.
Figure 4.4  Proposed 6H-1,3,4-thiadiazine SAR studies.
4.4.1 SAR of the Position 5 Substituent
As a first modification, analogues substituting the phenyl ring in position 5 of the
6H-1,3,4-thiadiazine moiety with various halogens 12(a-c), electron-withdrawing groups
12(d-f), and moderately electron-donating groups 12(g,h) (Tables 3 and 4) were
synthesized. As can be seen in Table 3, halogens attached to the 4-position of the phenyl
ring increased the potency against cdMMP-8, MMP-9 and cdMMP-14. This increase had
the maximum level with an appended chloro substituent in the case of MMP-9,
cdMMP-14 and with an appended bromo substituent in the case of cdMMP-8. However,
electron-withdrawing groups and moderately electron-donating groups at the 4-position of
the phenyl ring were well-tolerated by the tested MMPs (Table 4).
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Table 3.  In Vitro Activity of Halogenated 6H-1,3,4-Thiadiazine Derivatives.
MMPs Ki (µM)b
compd R formulaa mp (°C) method 1c 2 8 9c 12 13 14 14Ed
12a F C18H17FN4O3S2 166-167 B 0.44 0.45 0.19 0.16 0.28 0.65 0.44 nt
12b Cl C18H17ClN4O3S2 184-185 A 0.65 0.14 0.73 0.06 0.52 0.18 0.10 0.21
12c Br C18H17BrN4O3S2 180-181 A nt 0.27 0.11 0.16 0.44 0.37 0.34 nt
a Analytical results are within ±0.4% of the theoretical values. b MMP inhibition in vitro. Assays
were run at pH 7 against the catalytic domains of the enzymes. See the Experimental Section for
complete protocol. Standard deviations were typically ±15% of the mean or less. c Full-length
version of the enzyme was used. d The ectodomain of the enzyme was used. nt denotes not tested.
Surprisingly, the electron-withdrawing CN group of compound 12e, which can be
described as a pseudohalogen81, also improved inhibitory activity against MMP-9
comparable to the halogens. With the moderately electron-donating CH3 group compound
12h tended to have potency against cdMMP-12. Substitution by electron-withdrawing
substituents produces an electron-deficient phenyl ring, which in turn can improve
aryl-aryl stacking interactions with aromatic side-chains in the active site. The reduction in
affinity, resulting from a reduced aryl-aryl stack by phenyl rings para-substituted by
moderate electron-releasing groups (e.g. CH3), appears to be more than offset by the
increase in steric bulk/lipophilic contacts that these groups provide in the case of
cdMMP-12. Consequently, the replacement of the 4-methyl-phenyl ring in compound 12h
with the bulky adamantyl residue verified in compound 13a resulted in a 10 to 1000 fold
loss of inhibitory activity against the tested MMPs, with the exception of cdMMP-12
(Table 5). This enzyme was inhibited by 13a very selectively in the submicromolar range.
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Table 4.  In Vitro Activity of 6H-1,3,4-Thiadiazine Derivatives Substituted with Electron-
Withdrawing or Electron-Donating Functionalities.
MMPs Ki (µM)b
compd R formulaa mp (°C) method 1c 2 8 9c 12 13 14 14Ed
12d NO2 C18H17N5O5S2 201-202 A 0.26 0.30 0.17 0.13 0.28 0.26 0.29 nt
12e CN C19H17N5O3S2 186-187 A 0.39 0.24 0.22 0.08 0.37 0.25 0.24 0.40
12f CF3 C19H17F3N4O3S2 187-188 A 0.43 nt 0.26 0.24 0.30 0.57 0.58 0.39
12g OCH3 C19H20N4O4S2 192-193 A 0.58 0.52 0.18 0.32 0.34 1.33 0.59 nt
12h CH3 C19H20N4O3S2 184-185 A nt 0.41 0.30 0.16 0.11 0.62 0.38 nt
a-d See footnotes in Table 3. nt denotes not tested.
Table 5.  In Vitro Activity of 6H-1,3,4-Thiadiazine Derivatives with Different Position 5
Residues.
MMPs Ki (µM)b
compd R formulaa mp (°C) method 1c 2 8 9c 12 13 14 14Ed
13ae 1-adamantyl  C22H28N4O3S2 183-184 B nt >15 >15 >15 0.41 >15 3.07 nt
13b 5-Cl-thienyl  C16H15ClN4O3S3 198-199 B 0.45 1.87 0.18 0.17 0.24 0.47 0.32 0.20
a-d See footnotes in Table 3. e At high assay concentrations (>5µM) the compound showed
fluorescence quenching effects. nt denotes not tested.
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The bioisosteric82 replacement of the 4-chlorophenyl residue with a 5-chlorothienyl moiety
represented by compound 13b demonstrated enzyme selectivity between cdMMP-2 and
MMP-9 by a factor of 10.
4.4.2 SAR of the Sulfonamide Residue
The sulfonamide portion of the molecules and the influence of this group on enzyme
inhibition was also investigated.
Table 6.  Modifications of the Sulfonamide Residue.
MMPs Ki (µM)b
compd R formulaa mp (°C) method 1c 2 8 9c 12 13 14 14Ed
12b Ph C18H17ClN4O3S2 184-185 A 0.65 0.14 0.73 0.06 0.52 0.18 0.10 0.21
14a CH2Ph C19H19ClN4O3S2 169-170 A 0.36 0.09 0.20 0.04 0.48 0.12 0.19 0.18
14b 2-thienyl C16H15ClN4O3S3 175-176 A 1.04 0.55 0.06 0.80 0.36 3.81 0.25 nt
a-d See footnotes in Table 3. nt denotes not tested.
Since halogens attached to the 4-position of the phenyl ring resulted in potent MMPIs, the
chloro substituent was chosen to be kept constant within the compared structures. The
phenylsulfonamide analogue 12b, was determined to be a broad-spectrum inhibitor. The
more flexible benzylsulfonamide 14a was also prepared and tested for in vitro activity.
This compound possessed a slight increase of binding affinity with cdMMP-2,
cdMMP-13, and MMP-9, all of which are characterized by a deep S1' pocket. The results
obtained with the 2-thienylsulfonamide 14b were remarkable. Replacement of the phenyl
group by a thienyl substituent led to a significant shift in enzyme selectivity. The
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compound was found to be even more selective for cdMMP-8 (Ki = 60 nM) compared with
the other tested MMPs.
4.4.3 SAR of Variations of the α-Carbon Substituents
The substituents at the α-carbon of the N-sulfonylated amino acid residue of the
compounds were also modified. In order to determine, if either the R- or the S-isomer
binds tighter to the enzymes, enantiomeric pairs of most of the compounds were
synthesized. The results of the in vitro tests revealed that the corresponding R-isomers
were, in general, more potent than the parent S-isomers (Table 7). Replacement of the
methyl group with the bulky isopropyl substituent (compounds 15f and 15g) led to a
decrease of inhibitory activity against the tested MMPs. Attachment of a second methyl
group at the α-carbon was verified in compound 15h. This compound is the first example
of a potent non-chiral 6H-1,3,4-thiadiazine based MMP inhibitor with nanomolar affinity
for cdMMP-2 and MMP-9.
Table 7. Modifications of the α-Carbon Substituents.
MMPs Ki (µM)b
compd   R;R1;R2 formulaa mp (°C) method 1c 2 8 9c 12 13 14 14Ed
12a(S)  H;CH3;F C18H17FN4O3S2 166-167 B 0.44 0.45 0.19 0.16 0.28 0.65 0.44 nt
15a(R)  CH3;H;F C18H17FN4O3S2 167-168 B 0.63 0.34 0.35 0.05 0.35 0.30 0.39 0.33
12b(S)  H;CH3;Cl C18H17ClN4O3S2 184-185 A 0.65 0.14 0.73 0.06 0.52 0.18 0.10 0.21
15b(R)  CH3;H;Cl C18H17ClN4O3S2 183-184 A 0.21 0.50 0.15 0.08 0.32 0.14 0.05 0.21
12c(S)  H;CH3;Br C18H17BrN4O3S2 180-181 A nt 0.27 0.11 0.16 0.44 0.37 0.34 nt
15c(R)  CH3;H;Br C18H17BrN4O3S2 179-180 A 0.42 0.15 0.21 0.04 0.34 0.13 0.20 0.18
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Table 7 (Continued). Modifications of the α-Carbon Substituents.
MMPs Ki (µM)b
compd   R;R1;R2 formulaa mp (°C) method 1c 2 8 9c 12 13 14 14Ed
12e(S)   H;CH3;CN C19H17N5O3S2 186-187 A 0.39 0.24 0.22 0.08 0.37 0.25 0.24 0.40
15d(R)  CH3;H;CN C19H17N5O3S2 185-186 A 0.40 0.21 0.23 0.08 0.36 0.21 0.24 0.40
12h(S)   H;CH3;CH3 C19H20N4O3S2 184-185 A nt 0.41 0.30 0.16 0.11 0.62 0.38 nt
15e(R)  CH3;H;CH3 C19H20N4O3S2 183-184 A 0.46 0.44 0.22 0.21 0.09 0.32 0.29 0.15
15f(S)e H;(CH3)2CH;Cl C20H21ClN4O3S2 201-202 A nt 0.88 0.78 0.20 0.38 >15 0.74 nt
15g(R)e (CH3)2CH;H;Cl C20H21ClN4O3S2 189-190 A 0.55 0.85 4.37 >15 0.35 >15 0.59 0.33
15h       CH3;CH3;Cl C19H19ClN4O3S2 204-205 A 0.30 0.08 0.48 0.09 0.20 0.18 0.15 0.11
a-d See footnotes in Table 3. e At high assay concentrations (>5µM) the compound showed
fluorescence quenching effects. nt denotes not tested.
4.5 X-ray Crystallography
4.5.1  Crystal Structures of 6H-1,3,4-Thiadiazine-2-amide-Based MMPIs
In order to investigate the 6H-1,3,4-thiadiazine system further and to establish the inhibitor
structures for protein/ligand-docking experiments, single-crystal X-ray diffraction studies
were carried out on (2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenyl-
sulfonyl)amino]propanamide 12b, (2S)-N-[5-(5-chloro-2-thienyl)-6H-1,3,4-thiadiazin-2-
yl]-2-[(phenylsulfonyl)amino]propanamide 13b, (2S)-N-[5-(4-chloro-phenyl)-6H-1,3,4-
thiadiazin-2-yl]-2-[(2-thienylsulfonyl)amino]propanamide 14b, and (2R)-N-[5-(4-fluoro-
phenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]propanamide 15a.
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In all four compounds the thiadiazine ring deviates from planarity (Figures 4.5, 4.6, 4.8
and 4.9).83 For conformational analysis the puckering of the ring system may be described
as out-of-plane displacements of the vertexes of the symmetric flat polygon using group
theory. The method applicable to any real cyclic compound was introduced by Cremer and
Pople and refined by Evans and Boeyens.84,85 The analysis starts out from crystallographic
fractional coordinates and involves transformation first to a set of cartesian coordinates.
From these coordinates, a set of three parameters of pucker in the form of polar
coordinates (Q, θ, ϕ) is obtained. These coordinates map out the conformation of the ring
on the surface of a sphere with radius Q and with poles at θ = 0, 180°. Three basic
conformations  (chair,  boat  and  twist-boat) and three highly symmetric intermediate
conformations (envelope, half-chair and screw-boat)  are  located on the sphere, whereby
the name screw-boat is proposed for the 1,3-diplanar form.
Figure 4.5  The molecular structure of 12b showing the atom-numbering scheme. Displacement
ellipsoids are drawn at the 50% probability level and H atoms are shown as small spheres of
arbitrary radii.
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Table 8. Selected geometric parameters (Å, °) for 12b.
S1−C9 1.726  (3) N2−C9 1.338  (3)
N1−C7 1.284  (4) N3−C9 1.321  (3)
N1−N2 1.389  (3)
C9−N2−N1 128.6  (2)
Table 9. Hydrogen-bonding geometry (Å, °) for 12b.
D−H⋅⋅⋅A D−H H⋅⋅⋅A D⋅⋅⋅A D−H⋅⋅⋅A
N2−H2N⋅⋅⋅S1i 0.82  (4) 2.72  (4) 3.236  (3) 122  (3)
N2−H2N⋅⋅⋅O1i 0.82  (4) 2.56  (4) 3.375  (3) 173  (4)
N4−H4N⋅⋅⋅N3 0.90  (3) 2.31  (3) 2.661  (3) 103  (2)
Symmetry code: (i) x, y, 1 + z.
Figure 4.6  The molecular structure of 13b showing the two molecules and the atom-
numbering scheme. Displacement ellipsoids are drawn at the 50% probability level and H
atoms are shown as small spheres of arbitrary radii.
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Table 10. Selected geometric parameters (Å, °) for 13b.
S2−C7 1.750  (6) S5−C23 1.755  (6)
S2−C6 1.805  (7) S5−C22 1.817  (7)
N1−C5 1.286  (8) N5−C21 1.292  (8)
N1−N2 1.407  (7) N5−N6 1.423  (7)
N2−C7 1.286  (8) N6−C23 1.288  (8)
N3−C7 1.395  (8) N7−C23 1.396  (8)
Table 11. Hydrogen-bonding geometry (Å, °) for 13b.
D−H⋅⋅⋅A D−H H⋅⋅⋅A D⋅⋅⋅A D−H⋅⋅⋅A
N3−H3N⋅⋅⋅N6 0.88 2.09 2.956  (7) 168
N4−H4N⋅⋅⋅S4 0.88 2.77 3.456  (5) 136
N4−H4N⋅⋅⋅N5 0.88 2.08 2.842  (7) 145
N7−H7N⋅⋅⋅N2 0.88 2.11 2.983  (7) 172
N8−H8N⋅⋅⋅N1 0.88 2.04 2.882  (7) 160
The calculated puckering parameters are shown in Table 12. From this analysis the
thiadiazine moiety assumes a screw-boat conformation in all compounds. The large ϕ
value for molecule 1 of 14b and 13b indicate that the direction of the ring distortion is
towards an inverted screw-boat conformation. The difference between the screw-boat and
the inverted screw-boat conformation is illustrated in Figure 4.7.
Table 12. Ring Puckering Parameters for 6H-1,3,4-Thiadiazine Amide-Based MMPIs.
Puckering Parameters
compound Q [Å] θ [°] ϕ [°]
12b 0.567(3) 70.6(3) 39.9(3)
13b, molecule 1 0.634 109.5 217.1
13b, molecule 2 0.665 70.5 35.9
14b, molecule 1 0.585 110.5 215.4
14b, molecule 2 0.595 69.7 34.3
15a 0.618(2) 69.9(2) 33.1(3)
Chapter 4   Results and Discussion 35
Figure 4.7  Ring conformatins of 6H-1,3,4-thiadiazines.
Figure 4.8  The molecular structure of 14b showing the two molecules, one methanol
molecule and the atom-numbering scheme. Displacement ellipsoids are drawn at the 50%
probability level and H atoms are shown as small spheres of arbitrary radii.
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Table 13. Selected geometric parameters (Å, °) for 14b.
S1−C9 1.748  (4) S4−C25 1.746  (4)
S1−C8 1.800  (5) S4−C24 1.810  (5)
N1−C7 1.275  (5) N5−C23 1.279  (5)
N1−N2 1.412  (5) N5−N6 1.400  (5)
N2−C9 1.298  (5) N6−C25 1.298  (5)
N3−C9 1.379  (5) N7−C25 1.377  (6)
Table 14. Hydrogen-bonding geometry (Å, °) for 14b.
D−H⋅⋅⋅A D−H H⋅⋅⋅A D⋅⋅⋅A D−H⋅⋅⋅A
N3−H3N⋅⋅⋅N6 1.03  (5) 1.99  (5) 3.017  (5) 174  (4)
N4−H4N⋅⋅⋅N5 0.86  (4) 2.04  (4) 2.903  (5) 175  (4)
N7−H7N⋅⋅⋅N2 1.00  (6) 1.87  (6) 2.865  (5) 170  (6)
N8−H8N⋅⋅⋅O4i 0.76  (5) 2.19  (5) 2.927  (5) 162  (5)
Symmetry code: (i) 1 + y, x – 1, – z
Inspection of the compounds unit cell reveal that the molecules of compound 12b show a
short intramolecular NAlaH⋅⋅⋅Nexo hydrogen bond [N⋅⋅⋅N 2.661(3) Å] and are linked into
a chain along the c axis by NendoH⋅⋅⋅Sendo and NendoH⋅⋅⋅OAla hydrogen bonds [N⋅⋅⋅S
3.236(3) and N⋅⋅⋅O 3.375(3) Å] between neighbouring molecules. The molecules of
compound 13b and 14b are dimerized through NexoH⋅⋅⋅Nendo hydrogen bonds [N⋅⋅⋅N
2.956(7) and 2.983(7) Å (13b), N⋅⋅⋅N 2.865(5) and 3.017(5) Å (14b)]. In compound 15a
the molecules are connected antiparallel into a chain along the a axis by  NexoH⋅⋅⋅OAla
and NAlaH⋅⋅⋅Nendo hydrogen bonds [N⋅⋅⋅⋅O 2.907(6) and N⋅⋅⋅N 2.911(6) Å].
Table 15. Selected geometric parameters (Å, °) for 15a.
S1−C9 1.752  (4) N1−N2 1.404  (3)
S1−C8 1.816  (3) N2−C9 1.296  (4)
N1−C7 1.291  (4) N3−N9 1.403  (3)
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Table 16. Hydrogen-bonding geometry (Å, °) for 15a.
D−H⋅⋅⋅A D−H H⋅⋅⋅A D⋅⋅⋅A D−H⋅⋅⋅A
N3−H3N⋅⋅⋅O1i 0.90  (4) 2.01  (4) 2.907  (6) 174  (3)
N4−H4N⋅⋅⋅N2ii 0.88  (5) 2.06  (5) 2.911  (6) 163  (4)
Symmetry code: (i) 1/2 + x, 3/2 – y, 1 – z; (ii) x – 1/2, 3/2 – y, 1 – z.
Figure 4.9  The molecular structure of 15a showing the atom-numbering scheme.
Displacement ellipsoids are drawn at the 50% probability level and H atoms are shown as
small spheres of arbitrary radii.
In compounds 12b and 15a, there are two distinct S1C8 and S1C9 bond lengths,
which can be attributed to typical SCsp3 and SCsp2 bonds [average values 1.819(19)
and 1.751(17)Å].86 The two molecules of compound 13b and 14b show similar SC
bond lengths. These results are in accordance with the 6H tautomeric form of the
thiadiazine system. The endocyclic C9N2 distance in 15a is shorter than the exocyclic
C9N3 distance and corresponds to an N═Csp2 bond. The same applies to the two
molecules of  compound 13b and 14b. In contrast to this trend, the endocyclic C9N2
distance in 12b is slightly longer than the exocyclic C9N3 distance and corresponds to
an NCsp2 bond. These bond differences resemble the characteristic pattern of bond-
length changes introduced by an amido-imino tautomerism (prototropic shift) within the
6H-1,3,4-thiadiazine moiety.
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Scheme 4. The Prototropic Shift of 6H-1,3,4-Thiadiazine-2-amide-Based MMPIs.
As shown in Scheme 4, the geometry of compounds 13b, 14b and 15a is consistent with
the tautomer on the left-hand side, while the geometry of 12b is closer to that of the
tautomer on the right-hand side. Consequently, the endocyclic N atom close to the
exocyclic N atom is a hydrogen-bond acceptor in 13b, 14b and 15a, and a hydrogen-bond
donor in 12b. The opposite applies to the exocyclic N atom, which is a hydrogen-bond
donor in 13b, 14b and 15a, and a hydrogen-bond acceptor in 12b. This contributes to the
different hydrogen-bonding patterns in the crystal structures of the compounds described.
4.5.2  Binding of N-Allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine Hydro-
bromide to cdMMP-8
With the 5-(4-chlorophenyl)-6H-1,3,4-thiadiazine-2-amide-based MMPIs it was shown
that the 4-chloro substituent plays a decisive role in archiving binding affinity to the
enzymes. To prove this fact with 6H-1,3,4-thiadiazine-2-amine-based MMPIs the
compound N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide 16 was
synthesized. This compound shows remarkable potency against MMP-9 (Ki = 783 nM)
and excellent solubility in water. Thus, the crystal structure of the catalytic domain of
human neutrophil collagenase (cdMMP-8) complexed with 16 (Ki = 41 µM) was
determined at 2.7 Å resolution (Figure 4.11). This structure provides insights into key
enzyme/inhibitor interactions that play a role in the binding of 6H-1,3,4-thiadiazine-based
MMP inhibitors. These interactions are represented schematically in Figure 4.12.
Notably, the inhibitor is coordinated to the catalytic zinc cation via the exocyclic nitrogen
of the thiadiazine moiety. The ring nitrogens are involved in specific hydrogen bonds with
the backbone of cdMMP-8. The crystal structure of uncomplexed inhibitor 16 which
contains two molecules per asymmetric unit, reveals that the thiadiazine ring deviates from
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planarity. The calculated puckering parameters are Q = 0.651 Å for both molecules,
θ = 109.9° (molecule 1) and 109.7° (molecule 2) and ϕ = 218.8° (molecule 1) and 218.3°
(molecule 2). Thus, the thiadiazine moiety assumes a screw-boat conformation for both
molecules in the asymmetric unit. The large ϕ values indicate, that the direction of the ring
distortion is towards an inverted screw-boat conformation. The space group P21/c of the
uncomplexed 16 crystals implies an inversion center and thus, an equal subset of
molecules with the inverted and non-inverted screw-boat conformation in the crystal
structure.
Figure 4.10  The molecular structure of 16 showing the two molecules and the atom-
numbering scheme. Displacement ellipsoids are drawn at the 50% probability level and H
atoms are shown as small spheres of arbitrary radii. The hydrogen positions on all
endocyclic nitrogens are calculated as half occupied.
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Figure 4.11  The electron density at the active site of the catalytic domain of human neutrophil
collagenase (cdMMP-8) complexed with N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine.
Figure 4.12  Schematic diagram of binding interactions between N-allyl-5-(4-chlorophenyl)-6H-
1,3,4-thiadiazin-2-amine and cdMMP-8. Interatomic distances given in Ångstroms are those
observed between protein and inhibitor heteroatoms. Hydrogen positions are inferred from
heavier atom positions. Zn2+ is the catalytic zinc of cdMMP-8.
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By contrast, when complexed with cdMMP-8 the puckering parameters of the thiadiazine
ring are Q = 0.619 Å, θ = 71.3° and ϕ = 36.9°. This corresponds to the non-inverted
screw-boat conformation of the heterocycle and fits the 4-chloro substituted phenyl residue
into the S3 subsite formed by Phe-164, His-162 and Ser-151 on the unprimed side. Thus,
stabilization of the non-inverted screw-boat conformation of the thiadiazine core structure
is expected to result in an inhibitor with higher affinity. The allyl substituent is directed
towards the S1' pocket of cdMMP-8. The hydrogen on the endocyclic nitrogen closest to
the exocyclic nitrogen is prototropically shifted from the exocyclic nitrogen and stabilized
by a hydrogen bond to the carboxylate oxygen of Glu-198. This glutamate is conserved in
all zinc-proteinases, serving as the general base crucial for catalysis.87 The other double
bond nitrogen accepts a hydrogen bond from the backbone amide of Ala-163. The
endocyclic sulfur does not appear to interact with any protein group, but makes a specific
hydrogen bond to a structural water molecule. It is further required for electronic
delocalisation of charge within the thiadiazine ring, which is necessary for zinc(II)-ion
coordination. The electron density of the exocyclic nitrogen is directed to the catalytic zinc
and does not interact with the backbone. The unique hydrogen bonding of the thiadiazine
core explains why other related thiadiazines were not identified through the screening
effort. Furthermore, the complex structure rationalizes the selectivity profile of compound
16 towards certain MMPs. Significant enzyme differences are found for the MMPs at the
unprimed side of the enzyme cleft (S1-S3), as compared to the primed side (S1'-S3') where
most of the known inhibitors bind. In fact, the potency of N-allyl-5-(4-chlorophenyl)-6H-
1,3,4-thiadiazin-2-amine hydrobromide is remarkable, given that the inhibitor lacks a
substituent capable of filling the S1' pocket. Consequently, it makes sense to attach a
sulfonamide moiety to the thiadiazine core structure to improve primed side binding
affinity.
4.6 Protein/Ligand−Docking Experiments
To understand the observed SARs and to rationalize the specificity profile, the interaction
of compound 14b with the active site of cdMMP-8 was examined. Since suitable crystals
of a cdMMP-8/compound 14b complex could not be obtained for X-ray studies,
compound 14b was modeled with the help of the docking tool FlexX88 into the protein by
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using coordinates from the above described cdMMP-8/inhibitor complex structure as a
reference. The overall strategy for docking of flexible ligands within FlexX is incremental,
as described below. The only interactive step during a complex prediction run is the
selection of a base fragment. Conformations of the ligand are generated according to a
discrete raster. Bond lengths and angles are kept invariant as given in the input structure. A
set of up to 12 discrete torsion angle values is assigned to each acyclic single bond by
matching representative torsional fragments onto the ligand. Conformational preferences
are determined for each fragment by a statistical evaluation employing an experimental
database of small molecule structures while the receptor is regarded as rigid. The docking
algorithm in FlexX is based on the incremental construction strategy, which consists of
three phases: 1. Base selection. The first phase of the docking algorithm is the selection of
a connected part of the ligand, the base fragment. 2. Base placement. In the second phase,
the base fragment is placed into the active site independently of the rest of the ligand. 3.
Complex construction. In the last phase, called the construction phase, the ligand is
constructed in an incremental way, starting with the different placements of the base
fragment. The base fragment selection is performed interactively and the determined
fragment is regarded as a rigid object.
Figure 4.13  The fragment placing algorithm: mapping three interaction centers (yellow spheres)
of the ligand onto three discrete interaction points (yellow dots) in the active site defines a unique
transformation of the ligand into the active site.
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The interaction surfaces on the receptor side are approximated by finite sets of interaction
points. A transformation of the base fragment into the active site is uniquely defined by
mapping three interaction centers of the fragment onto three interaction points of the
receptor by simply superposing the three point pairs onto each other (assuming that the
points sets are not collinear). Two of these triangles are regarded δ-compatible, if the
corresponding edge lengths differ by at most δ and the corresponding corners have
compatible interaction types. Therefore, in the first step the base placement algorithm has
to solve the following problem: For each triangle of interaction centers of the base
fragment have to be found all δ-compatible triangles of interaction points in the active site
of the receptor. The second step of the base placement algorithm clusters the placements
according to an appropriate distance function. For this purpose, the rms deviation between
two placements was used. All placements inside the same cluster are combined to one
solution by merging the lists of interactions and recomputing a superposition of all
interaction centers of the ligand onto the interaction points of the receptor. In a third step, a
final overlap test is performed and for the non overlapping placements energies are
computed. The resulting free binding energy of the protein-ligand complex is estimated in
FlexX as the sum of free energy contributions from hydrogen bonds, ion-pair interactions,
hydrophobic and π-stacking interactions of aromatic groups, and lipophilic interactions.
The underlying assumption for the docking experiment performed here is, that the
orientation of the 5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine moiety in the binding
site of cdMMP-8 is highly conserved. This assumption appears to be reasonable, since the
interactions of this residue (Zn2+ coordination, a.o.) are highly favorable and specific. The
flexible ligand docking results (highest scoring binding modes) for 14b in cdMMP-8 were
calculated in the form of rms values between the crystallographic binding mode and the
docked binding mode of the core fragment. In Table 17 the first 10 placements produced
by the docking algorithm are shown. The highest-ranking solution no. 73 has a free
binding energy of ∆G = -24.2 kJ/mol and an rms value of 3.6 Å.
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Table 17. List of Docking Results generated by FlexX.
Surprisingly, in this binding prediction the thiophene ring does not occupy the S1' pocket,
but is positioned above the catalytic zinc. Such electrostatic interactions between the
positive charge of a cation and the negative partial charge of aromatic π clouds have been
proposed in molecular recognition processes and recently explored by experimental and
theoretical works.89 A physical model of this interaction has been reported in a review.90
The catalytic zinc ion is positioned on the normal vector to the aromatic thiophene ring at
5.1 Å distance.
Figure 4.14  View of the highest-ranking binding prediction of compound 14b in the active site of
cdMMP-8. Amino acid residues that form the binding cleft are labeled, and a solid
surface has been added.
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A similar interaction involving the catalytic zinc ion has already been described for the
complex between cdMMP-8 and batimastat, where the thiophene aromatic ring of the
inhibitor faces the cation at a distance of 4.5 Å.
The contribution of these attractive electrostatic interactions, albeit at a relatively large
distance, should not be neglected in the evaluation of the stabilization of the complex
model but has to be taken into account in the selectivity of compound 14b as well as other
compounds of this series. Further interactions contributing to the tight binding of 14b may
include oxygen- and sulfur-zinc ligation and specific hydrogen bonds. These occur
between the endocyclic N4 and Ala-163, one of the sulfonyl oxygen atoms and Ala-161
and the sulfonamide nitrogen of the inhibitor and Pro-217.
4.7 In Vitro Cell−Assay
The ability of mamma carcinoma cells to invade the surrounding tissue and form distant
metastases is closely related to their ability to disintegrate components of the surrounding
extracellular matrix. As outlined in chapter 2 several types of proteinases contribute to the
degradation of the ECM, namely, serine proteinases (e.g. plasmin, uPA), cysteine
proteinases (e.g. cathepsins B and L), and matrix metalloproteinases. Increased expression
of uPA and its membrane-bound receptor uPAR is closely correlated with an increase in
disease recurrence and with early death of mamma carcinoma patients. Cell membrane-
associated uPAR is a key molecule for the induction of pericellular proteolysis, as
plasminogen is efficiently activated to plasmin by cell surface-associated interactions with
uPAR-bound uPA. Plasmin is a broad-range serine protease that cleaves a variety of
extracellular matrix proteins. In addition plasmin can also activate MMPs such as MMP-2
and MMP-9.91 On this basis, it was postulated and shown at the "Institut für
Experimentelle Onkologie und Therapieforschung, TU München" that the inhibitor (2S)-
N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]propanamide
12b  inhibits the activity of MMP-2 and MMP-9 expressed by MDA-231 BAG mamma
carcinoma cells.92 The active and latent forms of MMP-9 and the latent form of MMP-2
were detected in the supernatants of the tumor cells by zymography. Compound 12b was
tested using a potent MMP inhibitor as a reference. The compounds were incubated under
cell culture conditions in a 5% CO2 atmosphere at 37°C for 24 hours. The final
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gelatinolytic activity of the tumor cells was measured using DQTM-gelatin (Molecular
probes, Eugene, OR, USA), which serves as a fluorescein-conjugated but fluorescence-
quenched protease substrate. On degradation of the substrate by gelatinases, the released
fluorescent peptides are quantified by a fluorescence reader (Wallac, Victor2 1420, Perkin
Elmer, Überlingen, Germany) at excitation and emission wavelengths of 485 nm and
535 nm, respectively. The increase in fluorescence is proportional to the gelatinolytic
activity. These results were compared to the gelatin degrading activity of the cell-line
without inhibitor. It was found, that the reference MMP-inhibitor reduced the gelatinolytic
activity by about 20 percent at 21 µM final assay concentration, while compound 12b
showed the same reduction at 10 µM final assay concentration.
Figure 4.15  Inhibition of the gelatinolytic activity of the mamma carcinoma cell-line MDA-231
BAG by 12b in comparison with a potent reference MMPI.
Since the reference MMP inhibitor was already tested in a synergic mouse lymphoma
model with great success, thiadiazine-based MMPIs are now attractive candidates for
in vivo tumor models.
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5 Conclusions
A series of potent matrix metalloproteinase inhibitors based on a 6H-1,3,4-thiadiazine
scaffold was discovered and optimized. The new compounds lacking a typical
zinc-coordinating group were tested against eight different matrix metalloproteinases,
MMP-1, cdMMP-2, cdMMP-8, MMP-9, cdMMP-12, cdMMP-13, cdMMP-14, and the
ectodomain of MMP-14. From a small number of screening hits exhibiting Ki -values in
the micromolar range against cdMMP-8, the optimization strategy led to compounds with
nanomolar inhibitory activity against cdMMP-2, cdMMP-8, MMP-9, and cdMMP-14.
This was primarily achieved by the attachment of a N-sulfonylated amino acid derivative
to the 6H-1,3,4-thiadiazine core fragment. From in-depth SAR examinations, optimum
enzyme inhibitory activity in the series generally was associated with the R configuration
at the amino acid chiral center. The non-chiral variant N-[5-(4-chlorophenyl)-6H-1,3,4-
thiadiazine-2-yl]-2-methyl-2-[(phenylsulfonyl)amino]propanamide was synthesized as
well and shows nanomolar affinity for cdMMP-2 and MMP-9. Variations of substituents
attached to the para-position of the phenyl ring in position 5 of the thiadiazine moiety
revealed a preference for halogens to produce potent and selective inhibitors. On the other
hand, the inhibition of MMP-1 and cdMMP-12 demonstrated very few variations in
potency as functional groups were altered. Inhibition of cdMMP-13 generally occured in
the micromolar to submicromolar range within the tested compound series. The most
potent inhibitors were readily prepared by standard peptide coupling reactions from
5-substituted 6H-1,3,4-thiadiazine-2-amine hydrohalides and N-sulfonylated amino acid
derivatives.
Using X-ray crystallography, a novel binding mode of N-allyl-5-(4-chloro-phenyl)-6H-
1,3,4-thiadiazin-2-amine in the active site of the catalytic domain of human neutrophil
collagenase was elucidated. In contrast to the established MMP-inhibitors, which
exclusively bind to the primed side, N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-
amine interact with both the primed and the unprimed side. The zinc-ligation is mediated
via the exocylic nitrogen while the endocyclic nitrogens of the thiadiazine system are
involved in specific hydrogen bonds with cdMMP-8. These results are in good agreement
with the postulated binding mode of the inhibitors. Analysis of the puckering parameters
of the 6H-1,3,4-thiadiazine system bound to cdMMP-8 reveal a preferential screw-boat
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conformation of the heterocycle. This is important in comparison with the crystal structure
of uncomplexed N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide
which consists of an equal subset of molecules with the inverted- and non-inverted
screw-boat conformation. Similar thiadiazine ring conformations were observed in the
crystal structures of the uncomplexed 6H-1,3,4-thiadiazin-2-amide-based MMPIs.
Docking experiments of  (2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(2-
thienylsulfonyl)amino]propanamide to cdMMP-8 reveal an unexpected binding mode of
the highest ranking binding prediction. In this prediction the thiophene ring may stabilize
the enzyme-inhibitor adduct by cation-aromatic interations. Furthermore, the
conformational rigidity of the compound and specific hydrogen bonds with the enzyme's
backbone may be advantageous as a means to obtain the observed selectivity.
On the basis of its in vitro activity (2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-
[(phenylsulfonyl)amino]propanamide was used for an in vitro cell assay with the mamma
carcinoma cell-line MDA-231 BAG to elucidate the anti-tumor activity of the compound
class. The promising results imply that 6H-1,3,4-thiadiazine-based MMPIs are now
attractive candidates for in vivo tumor models and further pharmacological trials.
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6 Experimental Section
6.1 General Information
All moisture-free operations were performed in oven dried glassware under a positive
pressure of argon. Sensitive liquids and solutions were transferred via syringe or cannula
and introduced into reaction vessels through rubber septa.
Proton (1H) nuclear magnetic resonance (NMR) spectra were measured with a Bruker
DRX-500 (500.1 MHz) spectrometer, and carbon thirteen (13C) NMR spectra were
measured with a Bruker DRX-500 (125.8 MHz) spectrometer, both at 22°C and with TMS
as an external standard. Chemical shifts are reported in parts per million (ppm, δ units).
Coupling constants are reported in units of hertz (Hz).
Mass spectral (MS) data were obtained on a Fisons Autospec VG spectrometer by the
DCI/methane and DEI/isobutane method. MALDI-TOF mass spectral data were obtained
on a PerSeptive Biosystems Voyager-DE spectrometer with DHB as the matrix and
PEG 200 as the calibration standard.
Elemental analyses were performed on a Leco CHNS-932 elemental analyzer
(microanalytical laboratory of the University of Bielefeld). All inhibitors synthesized in
the experiments below were analyzed by elemental analysis and the compounds had values
within the range of ±0.4% for CHN.
Melting points (mp) were determined with a Büchi 510 melting point apparatus and are
uncorrected.
Analytical purity was assessed by RP-HPLC using an Applied Biosystems 130A
Separation System. Compounds were detected at 230 nm. The stationary phase was an
Aquapore OD-300 C18 column (2.1 mm x 220 mm). The mobile phase employed aqueous
trifluoroacetic acid with acetonitrile as the organic modifier and a flow rate of 250 µL/min.
Solvent A = 0.1% TFA in water. Solvent B = 0.09% TFA and 80% acetonitrile in water.
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The following gradient was used: t = 0 min (0% B), t = 5 min (40% B), t = 25 min
(60% B), t = 30 min (100% B), t = 35 min (0% B). Analytical data is reported as retention
time, tR, in minutes.
Analytical TLC was performed on Alugram Sil G/UV254 pre-coated aluminium-backed
silica gel plates (Macherey-Nagel, Düren). Visualization of spots was effected by one of
the following techniques: (a) ultraviolet illumination and (b) immersion of the plate in a
3% solution of ninhydrin in ethanol followed by heating. Analytical data is reported as
"ratio of front"-values (Rf -values).
P.a. grade reagents and solvents were used without further purification except that
methylene chloride was destilled under argon from calcium hydride, and DMF was
destilled under argon on molecular sieve 3 Å. Most of the special organic starting
materials and reagents were obtained from Sigma-Aldrich, Deisenhofen, and Lancaster-
Synthesis, Mühlheim. Solvents were generally obtained from Merck, Darmstadt and
Baker, Groß-Gerau.
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6.2 Synthetic Methods
6.2.1 Aryl ω-Halo Ketones
2-Bromo-1-(5-chloro-2-thienyl)ethanone
A solution of 2-acetyl-5-chlorothiophene (1.28 g, 8 mmol) in 20 mL choroform was
cooled to 0°C. Pyridinium bromide perbromide (3.2 g, 10 mmol) was added in four
portions to the stirred solution over a period of 30 min. Upon completion of the reaction
(indicated by TLC) the solution was poured into ice water and extracted with ether. The
combined ether fractions were finally washed with water and saturated saline solution,
dried over MgSO4, and concentrated. The oily residue was triturated with petrolether
(40/80) and the resulting 2-bromo-1-(5-chloro-2-thienyl)ethanone was recrystallized from
petrolether giving 1.16 g (61%) of the pure product as colorless plates; mp: 70-72°C;
Rf = 0.78 (eluent: methanol/THF 3 : 1); 1H-NMR (DMSO-d6): δ 4.80 (s, 2H), 7.34 (d,
3J = 4.1 Hz, 1H), 7.98 (d, 3J = 4.2 Hz, 1H); 13C-NMR (DMSO-d6): δ 32.16 (CH2), 129.22,
135.18 (CH.), 138.85, 139.45 (C), 184.45 (C=O).
2-Bromo-1-[4-(trifluoromethyl)phenyl]ethanone
A solution of 4-trifluoromethyl-acetophenone (1.88 g, 10 mmol) in 40 mL methylene
chloride was heated to reflux. Within 1 h a solution of bromine (1.6 g, 10 mmol) in 20 mL
methylene chloride was added dropwise to the boiling solution under rapid stirring. During
reaction the resulting HBr gas was removed by a positive argon pressure. The orange
reaction mixture was stirred overnight at room temperature within which time it becomes
clear. The mixture was then evaporated under reduced pressure to give an off-white solid.
Recrystallization from petrolether/n-hexane afforded 2.36 g (88%) of the desired product
as colorless plates; mp: 53-54°C; Rf = 0.81 (eluent: methanol/THF 3 : 1); 1H-NMR
(CDCl3): δ 4.43 (s, 2H), 7.74 (d, 3J = 8.3 Hz, 2H), 8.08 (d, 3J = 8.2 Hz, 2H); 13C-NMR
(CDCl3): δ 30.31 (CH2), 123.37 (q, 1JCF = 272.9 Hz, CF3), 125.90, 129.31 (CH), 135.05
(q, 2JCF = 33.09 Hz, C-CF3), 136.56 (C-CO), 190.40 (C=O).
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6.2.2 Substituted 2-Amino-6H-1,3,4-thiadiazine Hydrohalides
General Procedure for Preparing Substituted 2-Amino-6H-1,3,4-thiadiazine
Hydrohalides (Method A)
2-Amino-5-(4-chlorophenyl)-6H-1,3,4-thiadiazine Hydrobromide (6c)
4-Chlorophenacylbromide (2.34 g, 10 mmol) and thiosemicarbazide (0.91 g, 10 mmol)
were suspended in 30 mL ethanol at 0°C. The mixture was allowed to warm up to room
temperature overnight under stirring. The resulting slurry was cooled to -20°C and the
precipitate was collected by filtration, washed with cold ethanol, and dried in vacuo. The
pale yellow solid was again suspended in 20 mL ethanol which contained 1mL of 48%
aqueous hydrobromic acid. The mixture was heated to reflux for 30 min and then allowed
to cool down to room temperature overnight. The precipitate was filtered, recrystallized
from ethanol, and dried in high-vacuo at 40°C over phosphorus pentoxide. Yield: 1.84 g
(60%); colorless needles; mp: 227°C; Rf = 0.52 (eluent: chloroform/methanol/glacial
acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6): δ 4.31 (s, 2H), 7.59 (d, 3J = 8.6
Hz, 2H), 7.90 (d, 3J = 8.7 Hz, 2H), 9.46 (br s, 1H), 10.11 (br s, 1H), 13.32 (br s, 1H);
13C-NMR (DMSO-d6): δ 22.10 (CH2), 128.81, 129.11 (CHarom.), 131.86, 136.22, 150.24,
164.17 (C). DEI MS: m/z 225 [M - HBr]+.
2-Amino-5-(4-bromophenyl)-6H-1,3,4-thiadiazine Hydrobromide (6d)
The compound was prepared starting from 4-bromophenacylbromide as described for
compound 6c. Yield: 2.33 g (66%); colorless crystals; mp: 218°C; Rf = 0.54 (eluent:
chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6):
δ 4.30 (s, 2H), 7.73 (d, 3J = 8.6 Hz, 2H), 7.83 (d, 3J = 8.6 Hz, 2H), 9.34 (br s, 1H), 10.09
(br s, 1H), 13.31 (br s, 1H); 13C-NMR (DMSO-d6): δ 22.04 (CH2), 125.16 (C), 128.96,
132.03 (CHarom.), 132.21, 150.34, 164.16 (C). DEI MS: m/z 270 [M - HBr]+.
2-Amino-5-(4-nitrophenyl)-6H-1,3,4-thiadiazine Hydrobromide (6e)
The title compound was prepared starting from 4-nitrophenacylbromide as described for
compound 6c. Yield: 1.58 g (49%); orange crystals; mp: 228°C; Rf = 0.53 (eluent:
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chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6):
δ 4.38 (s, 2H), 8.14 (d, 3J = 8.9 Hz, 2H), 8.34 (d, 3J = 8.9 Hz, 2H), 9.61 (br s, 1H), 10.21
(br s, 1H), 13.42 (br s, 1H); 13C-NMR (DMSO-d6): δ 22.22 (CH2), 124.07, 128.36
(CHarom.), 139.00, 148.76, 149.34, 164.25 (C). DEI MS: m/z 236 [M - HBr]+.
2-Amino-5-(4-cyanophenyl)-6H-1,3,4-thiadiazine Hydrobromide (6f)
The compound was prepared starting from 4-cyanophenacylbromide as described for
compound 6c. Yield: 1.80 g (61%); yellow needles; mp: 248°C; Rf = 0.49 (eluent:
chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6):
δ 4.35 (s, 2H), 8.00 (d, 3J = 8.4 Hz, 2H), 8.05 (d, 3J = 8.4 Hz, 2H), 9.93 (br s, 1H), 10.19
(br s, 1H), 13.33 (br s, 1H); 13C-NMR (DMSO-d6): δ 22.08 (CH2), 113.41, 118.30 (C),
127.74, 132.92 (CHarom.), 137.30, 149.68, 164.22 (C). DEI MS: m/z 216 [M - HBr]+.
2-Amino-5-(4-(trifluoromethyl)phenyl)-6H-1,3,4-thiadiazine Hydrobromide (6g)
The compound was prepared starting from 2-bromo-1-[4-(trifluoromethyl)phenyl]-
ethanone as described for compound 6c. Yield: 1.54 g (45%); colorless crystals;
mp: 224°C; Rf = 0.56 (eluent: chloroform/methanol/glacial acetic acid/ethylacetate
5 : 3 : 1 : 4); 1H-NMR (DMSO-d6): δ 4.36 (s, 2H), 7.90 (d, 3J = 8.3 Hz, 2H), 8.10
(d, 3J = 8.2 Hz, 2H), 9.92 (br s, 1H), 10.12 (br s, 1H), 13.13 (br s, 1H); 13C-NMR
(DMSO-d6): δ 22.17 (CH2), 123.88 (q, 1JCF = 272.3 Hz, CF3), 125.92, 127.86 (CHarom),
130.97 (q, 2JCF = 32.2 Hz, C-CF3), 137.01, 149.92, 164.18 (C). DEI MS: m/z 259
[M - HBr]+.
2-Amino-5-(4-methoxyphenyl)-6H-1,3,4-thiadiazine Hydrobromide (6h)
The title compound was prepared starting from 4-methoxyphenacylbromide as described
for compound 6c. Yield: 1.65 g (55%); pale yellow needles; mp: 185°C; Rf = 0.54 (eluent:
chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6):
δ 3.81 (s, 3H), 4.27 (s, 2H), 7.06 (d, 3J = 8.9 Hz, 2H), 7.85 (d, 3J = 8.9 Hz, 2H), 9.26 (br s,
1H), 9.85 (br s, 1H), 13.10 (br s, 1H); 13C-NMR (DMSO-d6): δ 22.07 (CH2), 55.54 (CH3),
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114.46 (CHarom.), 125.06 (C), 128.82 (CHarom.), 151.04, 161.85, 163.99 (C). DEI MS: m/z
221 [M - HBr]+.
2-Amino-5-(4-methylphenyl)-6H-1,3,4-thiadiazine Hydrobromide (6i)
The compound was prepared starting from 4-methylphenacylbromide (20 mmol) as
described for compound 6c. Yield: 3.13 g (55%); colorless crystals; mp: 220°C; Rf = 0.52
(eluent: chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR
(DMSO-d6): δ 2.35 (s, 3H), 4.29 (s, 2H), 7.33 (d, 3J = 8.0 Hz, 2H), 7.78 (d, 3J = 8.1 Hz,
2H), 9.31 (br s, 1H), 10.04 (br s, 1H), 13.23 (br s, 1H); 13C-NMR (DMSO-d6): δ 21.01
(CH2), 22.11 (CH3), 126.96, 129.61 (CHarom.), 130.13, 141.60, 151.28, 164.19 (C).
DEI MS: m/z 205 [M - HBr]+.
N-Allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine Hydrobromide (16)
4-Chlorophenacylbromide (2.34 g, 10 mmol) and 4-allylthiosemicarbazide (1.31 g,
10 mmol) were suspended in 30 mL ethanol at 0°C. The mixture was allowed to warm up
to room temperature overnight under stirring. The yellow solution was added dropwise to
50 mL ethylacetate at 0°C, and the precipitate was collected by filtration, washed with cold
ethanol, and dried in vacuo. The yellow solid was again suspended in 20 mL ethanol
which contained 1 mL of 48% aqueous hydrobromic acid. The mixture was heated to
reflux for 30 min and then allowed to cool down to room temperature overnight. After
addition of cold ethylacetate, the precipitate was filtered, recrystallized from
ethanol/ethylacetate (1 : 3), and dried in high-vacuo at 40°C over phosphorus pentoxide.
Yield: 1.49 g (43%); colorless crystals; mp: 210°C; Rf = 0.66 (eluent:
chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); HPLC (tR: 11.97);
1H-NMR (DMSO-d6): δ 4.17 (br s, 2H), 4.31 (s, 2H), 5.24-5.31 (m, 2H), 5.89 (m, 1H),
7.61 (d, 3J = 8.6 Hz, 2H), 7.92 (d, 3J = 8.6 Hz, 2H), 10.71 (br s, 1H), 12.87 (br s, 1H);
13C-NMR (DMSO-d6): δ 22.23 (CH2), 46.01 (CH2), 117.95 (=CH2), 128.82, 129.16
(CHarom.), 131.53 (=CH), 131.86, 136.28, 151.29 (C). DEI MS: m/z 265 [M - HBr]+;
MALDI-TOF-MS: m/z calculated for [M - Br]+: 266.1, found: 266.1. Analysis calculated
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for C12H13BrClN3S: C, 41.58%; H, 3.78%; N, 12.12%. Found: C, 41.59%; H, 3.67%; N,
12.10%.
General Procedure for Preparing 2-Amino-6H-1,3,4-thiadiazine Hydrohalides
(Method B)
2-Amino-5-phenyl-6H-1,3,4-thiadiazine Hydrochloride (6a)
Thiosemicarbazide Hydrochloride: This compound was obtained as colorless crystals by
evaporation of a hydrochloric acid solution of thiosemicarbazide.
A suspension of phenacylchloride 1.55 g (10 mmol) and thiosemicarbazide hydrochloride
1.72 g (10 mmol) in 25 mL methanol was heated to reflux for 15 min. After cooling down
to room temperature the white crystalline solid was filtered, recrystallized from methanol,
and dried in high-vacuo at 40°C over phosphorus pentoxide. Yield: 0.99 g (43%);
colorless needles; mp: 206°C; Rf = 0.43 (eluent: chloroform/methanol/glacial acetic
acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6): δ 4.29 (s, 2H), 7.50-7.56 (m, 3H),
7.87-7.89 (m, 2H), 9.63 (br s, 1H), 10.51 (br s, 1H), 13.73 (br s, 1H); 13C-NMR
(DMSO-d6): δ 21.97 (CH2), 126.97, 129.03, 131.40 (CHarom.), 133.06, 150.85, 164.95 (C).
DEI MS: m/z 225 [M - HCl]+.
2-Amino-5-(4-fluorophenyl)-6H-1,3,4-thiadiazine Hydrochloride (6b)
The compound was prepared starting from 4-fluorophenacylchloride as described for
compound 6a. Yield: 1.79 g (73%); colorless crystals; mp: 231°C; Rf = 0.50 (eluent:
chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6):
δ 4.28 (s, 2H), 7.34-7.38 (m, 2H), 7.92-7.96 (m, 2H), 9.59 (br s, 1H), 10.54 (br s, 1H),
13.74 (br s, 1H); 13C-NMR (DMSO-d6): δ 22.02 (CH2), 116.11 (d, 2JCF = 21.4 Hz,
CHarom.), 129.57 (d, 3JCF  = 8.8 Hz, CHarom.), 129.64, 149.95, 162.92, 164.94 (C). DEI MS:
m/z 209 [M - HCl]+.
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2-Amino-5-(2-adamantyl)-6H-1,3,4-thiadiazine Hydrobromide (6j)
Thiosemicarbazide Hydrobromide: This compound was obtained as colorless crystals by
evaporation of a 48% hydrobromic acid solution of thiosemicarbazide.
A suspension of 1-(2-bromoacetyl)-adamantane 2.57 g (10 mmol) and thiosemicarbazide
hydrobromide 1.72 g (10 mmol) in 25 mL methanol was heated to reflux for 15 min. After
cooling down to room temperature the white crystalline solid was filtered, recrystallized
from methanol, and dried in high-vacuo at 40°C over phosphorus pentoxide. Yield: 1.97 g
(60%); colorless crystals; mp: 251°C; Rf = 0.60 (eluent: chloroform/methanol/glacial
acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR (DMSO-d6): δ 1.61-1.68 (m, 6H), 1.75
(s, 6H), 1.98 (s, 3H), 3.79 (s, 2H), 9.11 (br s, 1H), 9.84 (br s, 1H), 12.91 (br s, 1H);
13C-NMR (DMSO-d6): δ 20.39 (CH2), 27.21 (CH), 35.82 (CH2), 38.18 (C), 162.87 (C),
164.84 (C). DEI MS: m/z 249 [M - HBr]+.
2-Amino-5-(5-chloro-2-thienyl)-6H-1,3,4-thiadiazine Hydrobromide (6k)
The title compound was prepared starting from 2-bromo-1-(5-chloro-2-thienyl)ethanone as
described for compound 6j. Yield: 0.35 g (11%); off-white solid; mp: 249°C; Rf = 0.47
(eluent: chloroform/methanol/glacial acetic acid/ethylacetate 5 : 3 : 1 : 4); 1H-NMR
(DMSO-d6): δ 4.35 (s, 2H), 7.28 (d, 3J = 4.1 Hz, 1H), 7.68 (d, 3J = 4.1 Hz, 1H), 9.63
(br s, 1H), 10.03 (br s, 1H), 13.19 (br s, 1H); 13C-NMR (DMSO-d6): δ 21.69 (CH2),
128.36, 131.47 (CH.), 133.86, 135.94, 146.13, 163.71 (C). DEI MS: m/z 231 [M - HBr]+.
6.2.3 N-Sulfonylated Amino Acids
General Procedure for Preparing N-Sulfonylated Amino Acids
(2S)-2-[(Phenylsulfonyl)amino]propanoic Acid (8a)
Benzenesulfonylchloride (1.80 g, 10 mmol) was added to a solution of L-alanine (1.07 g,
12 mmol) in aqueous potassium carbonate (20 mL, 1.1 M). Under vigorous stirring, the
mixture was carefully heated to 70°C for 30 min. The resulting clear solution was cooled
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in an ice bath and then acidified to pH 2.5 by the dropwise addition of concentrated
hydrochloric acid under stirring. The precipitate was collected by filtration and washed
with a minimum amount of ice-cold water. Recrystallization from distilled water yielded
1.42 g (62%) (2S)-2-[(phenylsulfonyl)amino]propanoic acid as a white crystalline solid;
mp: 123-125°C; Rf = 0.47 (eluent: chloroform/acetone/glacial acetic acid 9 : 1 : 0.3);
1H-NMR (DMSO-d6): δ 1.13 (d, 3J = 7.2 Hz, 3H), 3.76 (m, 1H), 7.54-7.61 (m, 3H), 7.78
(d, 3J = 7.4 Hz, 2H), 8.14 (d, 3J = 8.3 Hz, NH), 12.64 (s, COOH); 13C-NMR (DMSO-d6):
δ 18.43 (CH3), 51.15 (CH), 126.40, 129.06, 132.35 (CHarom.), 141.34 (C), 173.22 (COOH).
(2R)-2-[(Phenylsulfonyl)amino]propanoic Acid (8b)
This compound was prepared starting from D-alanine as described for compound 8a.
Yield: 1.65 g (72%); white solid; mp: 124-126°C; Rf = 0.47 (eluent: chloroform/
acetone/glacial acetic acid 9 : 1 : 0.3); 1H-NMR (DMSO-d6): δ 1.13 (d, 3J = 7.1 Hz, 3H),
3.76 (m, 1H), 7.54-7.62 (m, 3H), 7.78 (d, 3J = 7.5 Hz, 2H), 8.15 (d, 3J = 8.3 Hz, NH),
12.65 (s, COOH).
(2S)-2-[(2-Thienylsulfonyl)amino]propanoic Acid (8c)
The title compound was prepared starting from thiophene-2-sulfonylchloride as described
for compound 8a. Yield: 1.57 g (67%); white solid; mp: 85-87°C; Rf = 0.45 (eluent:
chloroform/acetone/glacial acetic acid 9 : 1 : 0.3); 1H-NMR (DMSO-d6): δ 1.17 (d,
3J = 7.3 Hz, 3H), 7.14 (m, 1H), 7.56 (d, 3J = 3.1 Hz, 1H), 7.89 (d, 3J = 4.8 Hz, 1H), 8.35
(d, 3J = 8.2 Hz, NH), 12.71 (s, COOH); 13C-NMR (DMSO-d6): δ 27.81 (CH3), 60.83
(CH), 137.09, 141.07, 141.99 (CHarom.), 151.69 (C), 182.67 (COOH).
(2S)-2-[(Benzylsulfonyl)amino]propanoic Acid (8d)
This compound was prepared starting from benzylsulfonylchloride as described for
compound 8a. Yield: 1.97 g (81%); white solid; mp: 125-127°C; Rf = 0.49 (eluent:
chloroform/acetone/glacial acetic acid 9 : 1 : 0.3); 1H-NMR (DMSO-d6): 1.23 (d,
3J = 7.3 Hz, 3H), 3.79 (m, 1H), 4.30 (d, 2JAB = 13.7 Hz, 1H), 4.35 (d, 2JAB = 13.6 Hz, 1H),
Chapter 6   Experimental Section 58
7.33-7.39 (m, 5H), 7.55 (d, 3J = 7.9 Hz, NH), 12.71 (s, COOH); 13C-NMR (DMSO-d6):
δ 18.67 (CH3), 51.30 (CH), 58.55 (CH2), 128.01, 128.26 (CHarom.), 130.40 (C), 130.91
(CHarom.), 174.20 (COOH).
(2S)-3-Methyl-2-[(phenylsulfonyl)amino]butyric Acid (8e)
The compound was prepared starting from L-valine as described for compound 8a. Yield:
1.75 g (68%); colorless needles; mp: 149°C; Rf = 0.56 (eluent: chloroform/acetone/glacial
acetic acid 9 : 1 : 0.3); 1H-NMR (DMSO-d6): δ 0.77 (d, 3J = 6.7 Hz, 3H), 0.80 (d,
3J = 6.7 Hz, 3H), 1.92 (m, 1H), 3.51 (m, 1H), 7.52-7.60 (m, 3H), 7.77 (d, 3J = 7.5 Hz, 2H),
8.02 (d, 3J = 9.2 Hz, NH), 12.58 (s, COOH); 13C-NMR (DMSO-d6): δ 17.85 (CH3), 19.03
(CH3), 30.41 (CH), 61.26 (CH), 126.52, 128.90, 132.27 (CHarom.), 141.19 (C), 172.21
(COOH).
(2R)-3-Methyl-2-[(phenylsulfonyl)amino]butyric Acid (8f)
This compound was prepared starting from D-valine as described for compound 8a. Yield:
1.73 g (67%); colorless needles; mp: 148-149°C; Rf = 0.56 (eluent: chloroform/
acetone/glacial acetic acid 9 : 1 : 0.3); 1H-NMR (DMSO-d6): δ 0.77 (d, 3J = 6.7 Hz, 3H),
0.80 (d, 3J = 6.7 Hz, 3H), 1.92 (m, 1H), 3.51 (m, 1H), 7.52-7.60 (m, 3H), 7.77 (d, 3J = 7.5
Hz, 2H),  8.02 (d, 3J = 9.2 Hz, NH), 12.58 (s, COOH).
2-Methyl-N-(phenylsulfonyl)alanine (8g)
The title compound was prepared starting from 2-aminoisobutyric acid as described for
compound 8a. Yield: 1.84 g (76%); colorless crystals; mp: 146-147°C; Rf = 0.53 (eluent:
chloroform/acetone/glacial acetic acid 9 : 1 : 0.3); 1H-NMR (DMSO-d6): δ 1.25 (s, 6H),
7.52-7.59 (m, 3H),  7.79-7.83 (m, 2H), 7.99 (s, NH), 12.55 (s, COOH); 13C-NMR
(DMSO-d6): δ 25.76 (CH3), 57.77 (C), 126.13, 128.92, 131.99 (CHarom.), 143.73 (C),
175.32 (COOH).
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6.2.4 Substituted 6H-1,3,4-Thiadiazine Amides
General Procedure for Preparing Substituted 6H-1,3,4-Thiadiazine Amides
(4S)-2,6-Dioxo-N-(5-phenyl-6H-1,3,4-thiadiazin-2-yl)hexahydro-4-pyrimidinecarbox-
amide (11)
To a suspension of 2-amino-5-phenyl-6H-1,3,4-thiadiazine hydrochloride (6a) (314 mg,
1.38 mmol), (S)-2,6-dioxohexahydropyrimidine-4-carboxylic acid (221 mg, 1.40 mmol),
and 1-hydroxybenzotriazole (190 mg, 1.40 mmol) in 5 mL of DMF at 0°C was added
4-methylmorpholine (190 µL, 1.72 mmol) followed by the addition of N-ethyl-N'-(3-
dimethyl-aminopropyl)-carbodiimide hydrochloride (275 mg, 1.43 mmol). After 48 h at
5°C, the mixture was diluted with 20 mL of 0.1 M hydrochloric acid and stirred for 30 min
at room temperature. The precipitate was filtered and washed successively with water, ice-
cold methanol and diethylether. After drying in vacuo the solid was recystallized from
methanol to yield 225 mg (49%) of the title compound as colorless crystals; mp: 198°C
(dec.); HPLC (tR: 11.30); 1H-NMR (DMSO-d6): δ 2.61 (m, 1H), 2.93 (m, 1H), 3.80 (s,
2H), 4.18 (m, 1H), 7.48-7.50 (m, 3H), 7.63 (s, 1H), 7.88-7.90 (m, 2H), 10.07 (s, 1H),
12.45 (br s, 1H); 13C-NMR (DMSO-d6): δ 21.63, 33.27 (CH2), 51.64 (CH), 126.95,
128.87, 130.61 (CHarom.), 133.97, 148.58, 153.63, 163.32 (C), one (C) and (C=O) were not
detected. DCI MS: m/z 332 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+:
332.1, found: 332.2; calculated for [M + Na]+: 354.1, found: 354.2, calculated for
[M + K]+: 370.0, found: 370.1. Analysis calculated for C14H13N5O3S: C, 50.75%; H,
3.95%; N, 21.14%. Found: C, 50.55%; H, 3.79%; N, 20.96%.
The following compounds were prepared according to the general procedure as described
for the preparation of compound 11 starting from compounds 6a-k (1.38 mmol) by
coupling with compounds 8a-g (1.40 mmol).
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(2S)-N-[5-(4-Fluorophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (12a)
Yield: 229 mg (40%); colorless needles from methanol/acetonitrile (5 : 1); mp:
166-167°C; HPLC (tR: 13.18); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.60 (d,
2JAB = 14.4 Hz, 1H), 3.70 (d, 2JAB = 14.5 Hz, 1H), 4.02 (m, 1H), 7.30-7.34 (m, 2H),
7.53-7.61 (m, 3H), 7.78-7.79 (m, 2H), 7.94-7.97 (m, 2H), 8.09 (d, 3J = 8.3 Hz, 1H), 12.02
(br s, 1H); 13C-NMR (DMSO-d6): δ 18.91 (CH3), 21.22 (CH2), 53.10 (CH), 115.83 (d,
2JCF  = 21.4 Hz, CHarom.), 126.46, 129.03 (CHarom.), 129.43 (d, 3JCF  = 8.8 Hz, CHarom.),
130.80 (C), 132.31 (CHarom.), 141.15, 147.44, 162.40, 164.38 (C), one (C=O) was not
detected. DCI MS: m/z 421 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+:
421.1, found: 421.0; calculated for [M + Na]+: 443.1, found: 443.0. Analysis calculated for
C18H17FN4O3S2: C, 51.42%; H, 4.08%; N, 13.32%. Found: C, 51.11%; H, 4.19%; N,
13.02%.
(2S)-N-[5-(4-Chlorophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (12b)
Yield: 294 mg (49%); colorless needles from methanol/acetonitrile (5 : 1); mp:
184-185°C; HPLC (tR: 13.70); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.60 (d,
2JAB = 14.6 Hz, 1H), 3.70 (d, 2JAB = 14.6 Hz, 1H), 4.01 (m, 1H), 7.53-7.61 (m, 5H),
7.78-7.80 (m, 2H), 7.92 (d, 3J = 8.6 Hz, 2H), 8.09 (d, 3J = 8.2 Hz, 1H), 12.05 (br s, 1H);
13C-NMR (DMSO-d6): δ 18.88 (CH3), 21.04 (CH2), 53.07 (CH), 126.46, 128.76, 128.87,
129.02, 132.30 (CHarom.), 133.12, 135.18, 141.12, 147.34 (C), one (C) and (C=O) were not
detected. DCI MS: m/z 437 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+:
437.1, found: 437.1; calculated for [M + Na]+: 459.0, found: 459.1. Analysis calculated for
C18H17ClN4O3S2: C, 49.48%; H, 3.92%; N, 12.82%. Found: C, 49.20%; H, 3.90%; N,
12.67%.
(2S)-N-[5-(4-Bromophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (12c)
Yield: 340 mg (51%); colorless crystals from methanol/acetonitrile (10 : 1); mp:
180-181°C; HPLC (tR: 13.92); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.60 (d,
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2JAB = 14.5 Hz, 1H), 3.70 (d, 2JAB = 14.6 Hz, 1H), 4.00 (m, 1H), 7.53-7.61 (m, 3H), 7.69
(d, 3J = 8.4 Hz, 2H), 7.78 (d, 3J = 7.3 Hz, 2H), 7.84 (d, 3J = 8.4 Hz, 2H), 8.09 (d, 3J = 8.0
Hz, 1H), 12.01 (br s, 1H); 13C-NMR (DMSO-d6): δ 18.89 (CH3), 21.01 (CH2), 53.07 (CH),
124.05 (C), 126.46, 128.98, 129.03, 131.80, 132.31 (CHarom.), 133.48, 141.11, 147.45 (C),
one (C) and (C=O) were not detected. DCI MS: m/z 481 [M + H]+; MALDI-TOF-MS: m/z
calculated for [M + H]+: 481.0, found: 481.0; calculated for [M + Na]+: 503.0, found:
503.0; calculated for [M + K]+: 519.0, found: 519.0. Analysis calculated for
C18H17BrN4O3S2: C, 44.91%; H, 3.56%; N, 11.64%. Found: C, 44.96%; H, 3.53%; N,
11.58%.
(2S)-N-[5-(4-Nitrophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (12d)
Yield: 278 mg (45%); yellow crystals from methanol/acetonitrile (5 : 1); mp: 201-202°C;
HPLC (tR: 13.30); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.0 Hz, 3H), 3.68 (d, 2JAB = 14.6
Hz, 1H), 3.78 (d, 2JAB = 14.7 Hz, 1H), 4.03 (m, 1H), 7.53-7.61 (m, 3H), 7.79 (d, 3J = 7.4
Hz, 2H), 8.15 (m, 3H), 8.31 (m, 2H), 12.15 (br s, 1H); 13C-NMR (DMSO-d6): δ 18.82
(CH3), 20.99 (CH2), 53.04 (CH), 123.93, 126.47, 128.19, 129.04, 132.33 (CHarom.),
140.32, 141.09, 146.65, 148.17 (C), one (C) and (C=O) were not detected. DCI MS: m/z
448 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+: 448.1, found: 448.0;
calculated for [M + Na]+: 470.1, found: 470.1; calculated for [M + K]+: 486.0, found:
486.0. Analysis calculated for C18H17N5O5S2: C, 48.31%; H, 3.83%; N, 15.65%. Found: C,
48.29%; H, 4.04%; N, 15.80%.
(2S)-N-[5-(4-Cyanophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (12e)
Yield: 375 mg (64%); yellow crystals from methanol; mp: 186-187°C; HPLC (tR: 12.98);
1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.64 (d, 2JAB = 14.7 Hz, 1H), 3.75 (d,
2JAB = 14.7 Hz, 1H), 4.02 (m, 1H), 7.53-7.61 (m, 3H), 7.78-7.83 (m, 2H), 7.95 (d, 3J = 8.4
Hz, 2H), 8.07 (d, 3J = 8.3 Hz, 2H), 8.12 (d, 3J = 7.6 Hz, 1H), 12.11 (br s, 1H); 13C-NMR
(DMSO-d6): δ 18.83 (CH3), 20.89 (CH2), 53.03 (CH), 112.48, 118.51 (C), 126.46, 127.69,
129.03, 132.32, 132.74 (CHarom.), 138.55, 141.09, 146.96 (C), one (C) and (C=O) were not
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detected. DCI MS: m/z 428 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+:
428.1, found: 428.0; calculated for [M + Na]+: 450.1, found: 450.0; calculated for
[M + K]+: 466.0, found: 466.0. Analysis calculated for C19H17N5O3S2: C, 53.38%; H,
4.01%; N, 16.38%. Found: C, 53.38%; H, 4.08%; N, 16.35%.
(2S)-2-[(Phenylsulfonyl)amino]-N-{5-[4-(trifluoromethyl)phenyl]-6H-1,3,4-thia-
diazine-2-yl}propanamide (12f)
Yield: 396 mg (61%); colorless needles from methanol/acetonitrile (5 : 1); mp:
187-188°C; HPLC (tR: 14.17); 1H-NMR (DMSO-d6): δ 1.17 (d, 3J = 7.0 Hz, 3H), 3.66 (d,
2JAB = 14.7 Hz, 1H), 3.76 (d, 2JAB = 14.6 Hz, 1H), 4.03 (m, 1H), 7.54-7.61 (m, 3H), 7.79
(d, 3J = 7.4 Hz, 2H), 7.84 (d, 3J = 8.2 Hz, 2H), 8.10-8.12 (m, 3H), 12.10 (br s, 1H);
13C-NMR (DMSO-d6): δ 18.85 (CH3), 21.07 (CH2), 53.07 (CH), 122.14 (C), 124.03
(q, 1JCF = 272.3 Hz, CF3), 125.11, 125.69, 127.76, 129.03 (CHarom.), 130.14 (q, 2JCF = 31.9
Hz, C-CF3), 132.32 (CHarom.), 138.55, 141.09, 146.96 (C), one (C=O) was not detected.
DCI MS: m/z 471 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+: 471.1, found:
471.1; calculated for [M + Na]+: 493.1, found: 493.1. Analysis calculated for
C19H17F3N4O3S2: C, 48.50%; H, 3.64%; N, 11.91%. Found: C, 48.62%; H, 3.33%; N,
12.00%.
(2S)-N-[5-(4-Methoxyphenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (12g)
Yield: 345 mg (58%); colorless plates from methanol/acetonitrile (5 : 1); mp: 192-193°C;
HPLC (tR: 12.95); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.0 Hz, 3H), 3.57 (d, 2JAB = 14.5
Hz, 1H), 3.67 (d, 2JAB = 14.5 Hz, 1H), 3.80 (s, 3H), 3.99 (m, 1H), 7.03 (d, 3J = 8.6 Hz,
2H), 7.53-7.61 (m, 3H), 7.79 (d, 3J = 7.4 Hz, 2H), 7.86 (d, 3J = 8.6 Hz, 2H), 8.06 (d,
3J = 7.3 Hz, 1H), 11.99 (br s, 1H); 13C-NMR (DMSO-d6): δ 18.98 (CH3), 21.22 (CH2),
53.22 (CH), 55.38 (CH3), 114.22, 126.47, 128.69, 129.02 (CHarom.), 129.70 (C), 132.30
(CHarom.), 141.15, 148.03, 161.11 (C), one (C) and (C=O) were not detected. DCI MS: m/z
433 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+: 433.1, found: 433.2;
calculated for [M + Na]+: 455.1, found: 455.2. Analysis calculated for C19H20N4O4S2: C,
52.76%; H, 4.66%; N, 12.95%. Found: C, 52.67%; H, 4.53%; N, 13.00%.
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(2S)-N-[5-(4-Methylphenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (12h)
Yield: 314 mg (55%); colorless needles from methanol; mp: 186-187°C; HPLC
(tR: 13.44); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.0 Hz, 3H), 2.34 (s, 3H), 3.58 (d,
2JAB = 14.5 Hz, 1H), 3.68 (d, 2JAB = 14.5 Hz, 1H), 4.00 (m, 1H), 7.29 (d, 3J = 7.9 Hz, 2H),
7.53-7.61 (m, 3H), 7.78-7.80 (m, 4H), 8.06 (d, 3J = 7.9 Hz, 1H), 12.02 (br s, 1H). DCI
MS: m/z 417 [M + H]+. Analysis calculated for C19H20N4O3S2: C, 54.79%; H, 4.84%; N,
13.45%. Found: C, 54.78%; H, 4.86%; N, 13.42%.
(2S)-N-[5-(1-Adamantyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]propan-
amide (13a)
Yield: 420 mg (66%); colorless prisms from methanol/acetonitile (5 : 1); mp: 183-184°C;
HPLC (tR: 14.70); 1H-NMR (DMSO-d6): δ 1.11 (d, 3J = 7.1 Hz, 3H), 1.64-1.70 (m, 6H),
1.77 (s, 6H), 1.99 (s, 3H), 3.14 (d, 2JAB = 14.5 Hz, 1H), 3.18 (d, 2JAB = 14.9 Hz, 1H), 3.91
(m, 1H), 7.51-7.59 (m, 3H), 7.77 (d, 3J = 7.2 Hz, 2H), 7.95 (d, 3J = 7.5 Hz, 1H), 11.89
(br s, 1H); 13C-NMR (DMSO-d6): δ 18.99 (CH3), 20.07 (CH2), 27.32 (CH), 35.95 (CH2),
38.55 (C), 53.59 (CH), 126.38, 128.91, 132.14 (CHarom.), 141.19, 159.80 (C), one (C) and
(C=O) were not detected. DCI MS: m/z 461 [M + H]+; MALDI-TOF-MS: m/z calculated
for [M + H]+: 461.2, found: 461.0; calculated for [M + Na]+: 483.2, found: 483.1. Analysis
calculated for C22H28N4O3S2: C, 57.37%; H, 6.13%; N, 12.16%. Found: C, 57.19%; H,
6.24%; N, 11.92%.
(2S)-N-[5-(5-Chloro-2-thienyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (13b)
Yield: 216 mg (35%); colorless needles from methanol/acetonitrile (5 : 1); mp:
198-199°C; HPLC (tR: 13.67); 1H-NMR (DMSO-d6): δ 1.13 (d, 3J = 6.9 Hz, 3H), 3.56 (d,
2JAB = 16.1 Hz, 1H), 3.65 (d, 2JAB = 16.0 Hz, 1H), 4.03 (m, 1H), 7.22 (d, 3J = 3.7 Hz, 1H),
7.53-7.61 (m, 4H), 7.77-7.79 (m, 2H), 8.13 (d, 3J = 7.5 Hz, 1H), 11.85 (br s, 1H);
13C-NMR (DMSO-d6): δ 18.80 (CH3), 20.27 (CH2), 52.54 (CH), 127.30, 127.97, 129.04,
129.83, 132.35 (CHarom.), 132.49, 138.18, 141.03, 143.49 (C), one (C) and (C=O) were not
detected. DCI MS: m/z 443 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+:
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443.0, found: 443.0; calculated for [M + Na]+: 465.0, found: 465.0. Analysis calculated for
C16H15ClN4O3S3: C, 43.38%; H, 3.41%; N, 12.65%. Found: C, 43.18%; H, 3.04%; N,
12.46%.
(2S)-2-[(Benzylsulfonyl)amino]-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-
propanamide (14a)
Yield: 288 mg (46%); colorless needles from methanol/acetonitrile (5 : 1); mp:
169-170°C; HPLC (tR: 14.03); 1H-NMR (DMSO-d6): δ 1.26 (d, 3J = 7.1 Hz, 3H), 3.68 (d,
2JAB = 14.1 Hz, 1H), 3.81 (d, 2JAB = 14.5 Hz, 1H), 4.00 (m, 1H), 4.32 (d, 2JAB = 14.0 Hz,
1H), 4.35 (d, 2JAB = 14.0 Hz, 1H), 7.33-7.39 (m, 5H), 7.50 (d, 3J = 6.2 Hz, 1H), 7.56 (d,
3J = 8.5 Hz, 2H), 7.93 (d, 3J = 8.4 Hz, 2H), 12.12 (br s, 1H); 13C-NMR (DMSO-d6):
δ 19.18 (CH3), 21.19 (CH2), 53.12 (CH), 58.64 (CH2), 127.98, 128.24, 128.74, 128.90
(CHarom.), 130.32 (C), 130.86 (CHarom.), 133.10, 135.20, 147.41 (C), one (C) and (C=O)
were not detected. DCI MS: m/z 451 [M + H]+; MALDI-TOF-MS: m/z calculated for
[M + H]+: 451.1, found: 451.3; calculated for [M + Na]+: 473.1, found: 473.3; calculated
for [M + K]+: 489.0, found: 489.3. Analysis calculated for C19H19ClN4O3S2: C, 50.60%;
H, 4.25%; N, 12.42%. Found: C, 50.67%; H, 3.90%; N, 12.49%.
(2S)-N-[5-(4-Chlorophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(2-thienylsulfonyl)amino]-
propanamide (14b)
Yield: 301 mg (49%); colorless plates from methanol/acetonitile (5 : 1); mp: 175-176°C;
HPLC (tR: 13.62); 1H-NMR (DMSO-d6): δ 1.19 (d, 3J = 7.1 Hz, 3H), 3.61 (d, 2JAB = 14.5
Hz, 1H), 3.76 (d, 2JAB = 14.6 Hz, 1H), 4.08 (m, 1H), 7.14 (m, 1H), 7.55-7.56 (m, 3H), 7.89
(d, 3J = 4.9 Hz, 1H), 7.90 (d, 3J = 8.5 Hz, 2H), 8.30 (d, 3J = 6.9 Hz, 1H), 12.07 (br s, 1H);
13C-NMR (DMSO-d6): δ 18.81 (CH3), 21.11 (CH2), 53.12 (CH), 127.54, 128.75, 128.88,
131.62, 132.51 (CHarom.), 133.11, 135.18, 142.02, 147.37 (C), one (C) and (C=O) were not
detected. DCI MS: m/z 443 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+:
443.0, found: 443.0; calculated for [M + Na]+: 465.0, found: 465.0. Analysis calculated for
C16H15ClN4O3S3 ∙ 0.25 CH3OH: C, 43.40%; H, 3.57%; N, 12.40%. Found: C, 43.40%; H,
3.62%; N, 12.55%.
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(2R)-N-[5-(4-Fluorophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (15a)
Yield: 225 mg (39%); colorless needles from methanol/acetonitrile (5 : 1); mp:
167-168°C; HPLC (tR: 13.17); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.60 (d,
2JAB = 14.4 Hz, 1H), 3.70 (d, 2JAB = 14.5 Hz, 1H), 4.02 (m, 1H), 7.30-7.34 (m, 2H),
7.53-7.61 (m, 3H), 7.78-7.79 (m, 2H), 7.94-7.97 (m, 2H), 8.09 (d, 3J = 8.3 Hz, 1H), 12.02
(br s, 1H). DCI MS: m/z 421 [M + H]+. Analysis calculated for C18H17FN4O3S2: C,
51.42%; H, 4.08%; N, 13.32%. Found: C, 51.27%; H, 4.25%; N, 13.22%.
(2R)-N-[5-(4-Chlorophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (15b)
Yield: 308 mg (51%); colorless needles from methanol/acetonitrile (5 : 1); mp:
183-184°C; HPLC (tR: 13.18); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.60 (d,
2JAB = 14.6 Hz, 1H), 3.70 (d, 2JAB = 14.6 Hz, 1H), 4.01 (m, 1H), 7.53-7.61 (m, 5H),
7.78-7.80 (m, 2H), 7.92 (d, 3J = 8.6 Hz, 2H), 8.09 (d, 3J = 8.2 Hz, 1H), 12.04 (br s, 1H).
DCI MS: m/z 437 [M + H]+. Analysis calculated for C18H17ClN4O3S2: C, 49.48%;
H, 3.92%; N, 12.82%. Found: C, 49.22%; H, 3.53%; N, 12.86%.
(2R)-N-[5-(4-Bromophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (15c)
Yield: 365 mg (55%); colorless crystals from methanol/acetonitrile (10 : 1); mp:
179-180°C; HPLC (tR: 13.90); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.60 (d,
2JAB = 14.5 Hz, 1H), 3.70 (d, 2JAB = 14.6 Hz, 1H), 4.00 (m, 1H), 7.53-7.61 (m, 3H), 7.69
(d, 3J = 8.4 Hz, 2H), 7.78 (d, 3J = 7.3 Hz, 2H), 7.84 (d, 3J = 8.4 Hz, 2H), 8.10 (d, 3J = 8.0
Hz, 1H), 12.05 (br s, 1H). DCI MS: m/z 481 [M + H]+. Analysis calculated for
C18H17BrN4O3S2: C, 44.91%; H, 3.56%; N, 11.64%. Found: C, 45.24%; H, 3.62%; N,
11.40%.
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(2R)-N-[5-(4-Cyanophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (15d)
Yield: 386 mg (65%); yellow crystals from methanol; mp: 185-186°C; HPLC (tR: 13.02);
1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.1 Hz, 3H), 3.64 (d, 2JAB = 14.7 Hz, 1H), 3.75 (d,
2JAB = 14.7 Hz, 1H), 4.02 (m, 1H), 7.53-7.61 (m, 3H), 7.78-7.83 (m, 2H), 7.95 (d, 3J = 8.4
Hz, 2H), 8.07 (d, 3J = 8.3 Hz, 2H), 8.12 (d, 3J = 7.6 Hz, 1H), 12.11 (br s, 1H). DCI MS:
m/z 428 [M + H]+. Analysis calculated for C19H17N5O3S2: C, 53.38%; H, 4.01%; N,
16.38%. Found: C, 53.42%; H, 4.05%; N, 16.41%.
(2R)-N-[5-(4-Methylphenyl)-6H-1,3,4-thiadiazine-2-yl]-2-[(phenylsulfonyl)amino]-
propanamide (15e)
Yield: 308 mg (54%); colorless needles from methanol; mp: 183-184°C; HPLC
(tR: 13.42); 1H-NMR (DMSO-d6): δ 1.15 (d, 3J = 7.0 Hz, 3H), 2.34 (s, 3H), 3.58 (d,
2JAB = 14.5 Hz, 1H), 3.68 (d, 2JAB = 14.5 Hz, 1H), 4.00 (m, 1H), 7.29 (d, 3J = 7.9 Hz, 2H),
7.53-7.61 (m, 3H), 7.78-7.80 (m, 4H), 8.06 (d, 3J = 7.9 Hz, 1H), 12.02 (br s, 1H);
13C-NMR (DMSO-d6): δ 18.94 (CH3), 20.94 (CH3),  21.23 (CH2), 53.22 (CH), 126.46,
126.94, 129.01, 129.40 (CHarom.), 131.41 (C), 132.29 (CHarom.), 140.37, 141.15, 148.30
(C), one (C) and (C=O) were not detected. DCI MS: m/z 417 [M + H]+; MALDI-TOF-MS:
m/z calculated for [M + H]+: 417.1, found: 417.1; calculated for [M + Na]+: 439.1, found:
439.1; calculated for [M + K]+: 455.1, found: 455.1. Analysis calculated for
C19H20N4O3S2: C, 54.79%; H, 4.84%; N, 13.45%. Found: C, 54.77%; H, 4.88%; N,
13.43%.
(2S)-N-[5-(4-Chlorophenyl)-6H-1,3,4-thiadiazine-2-yl]-3-methyl-2-[(phenylsulfonyl)-
amino]butanamide (15f)
Yield: 324 mg (51%); colorless needles from methanol/acetonitrile (5 : 1); mp:
201-202°C; HPLC (tR: 14.42); 1H-NMR (DMSO-d6): 0.77 (d, 3J = 6.8 Hz, 3H), 0.80
(d, 3J = 6.7 Hz, 3H), 1.93 (m, 1H), 3.54 (d, 2JAB = 14.5 Hz, 1H), 3.64 (d, 2JAB = 14.6 Hz,
1H), 3.76 (m, 1H), 7.49-7.57 (m, 5H), 7.76 (d, 3J = 7.2 Hz, 2H), 7.91-7.93 (m, 3H), 11.95
(br s, 1H); 13C-NMR (DMSO-d6): 17.95 (CH3), 19.11 (CH3), 21.00 (CH2), 30.90 (CH),
50.66 (CH), 126.55, 128.82, 132.18 (CHarom.), 133.18, 135.15, 140.99, 147.31 (C), one (C)
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and (C=O) were not detected. DCI MS: m/z 465 [M + H]+; MALDI-TOF-MS: m/z
calculated for [M + H]+: 465.1, found: 465.0; calculated for [M + Na]+: 487.1, found:
487.0. Analysis calculated for C20H21ClN4O3S2: C, 51.66%; H, 4.55%; N, 12.05%. Found:
C, 51.70%; H, 4.34%; N, 12.03%.
(2R)-N-[5-(4-Chlorophenyl)-6H-1,3,4-thiadiazine-2-yl]-3-methyl-2-[(phenylsulfonyl)-
amino]butanamide (15g)
Yield: 359 mg (56%); colorless needles from methanol/acetonitrile (5 : 1); mp:
189-190°C; HPLC (tR: 14.45); 1H-NMR (DMSO-d6): 0.77 (d, 3J = 6.8 Hz, 3H), 0.80
(d, 3J = 6.7 Hz, 3H), 1.93 (m, 1H), 3.54 (d, 2JAB = 14.5 Hz, 1H), 3.64 (d, 2JAB = 14.6 Hz,
1H), 3.76 (m, 1H), 7.49-7.57 (m, 5H), 7.76 (d, 3J = 7.2 Hz, 2H), 7.91-7.93 (m, 3H), 11.95
(br s, 1H). DCI MS: m/z 465 [M + H]+. Analysis calculated for C20H21ClN4O3S2:
C, 51.66%; H, 4.55%; N, 12.05%. Found: C, 51.75%; H, 4.53%; N, 12.07%.
N-[5-(4-Chlorophenyl)-6H-1,3,4-thiadiazine-2-yl]-2-methyl-2-[(phenylsulfonyl)-
amino]propanamide (15h)
Yield: 239 mg (38%); colorless needles from methanol/acetonitrile (5 : 1); mp:
204-205°C; HPLC (tR: 14.17); 1H-NMR (DMSO-d6): 1.31 (s, 3H), 1.78 (s, 3H), 3.57
(m, 1H), 3.75 (m, 1H), 7.42 (m, 1H), 7.54-7.57 (m, 3H), 7.67 (m, 1H), 7.74 (m, 1H), 7.82
(m, 1H), 7.90 (m, 1H), 8.05-8.10 (m, 2H), 12.11 (br s, 1H); 13C-NMR (DMSO-d6): 21.63
(CH2), 24.13 (CH3), 66.85 (C), 126.30, 127.77, 128.15, 128.88, 129.04, 129.36 (CHarom.),
133.82 (C), 134.01 (CHarom.), 134.52, 135.16, 139.09, 149.85, 160.63, 173.79 (C).
DCI MS: m/z 451 [M + H]+; MALDI-TOF-MS: m/z calculated for [M + H]+: 451.1, found:
451.7; calculated for [M + Na]+: 473.1, found: 473.7. Analysis calculated for
C19H19ClN4O3S2: C, 50.60%; H, 4.25%; N, 12.42%. Found: C, 50.69%; H, 4.33%; N,
12.31%.
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6.3 Enzyme Preparations
MMP-1 from human rheumatoid synovial fibroblasts was purchased from Calbiochem-
Novabiochem Corporation, La Jolla.
Preparation of the recombinant catalytic domain of human gelatinase A (cdMMP-2): The
catalytic domain of pro-gelatinase A was prepared using an E. coli expression system.93
The proenzyme was activated with 0.5 mM APMA at 37°C prior to use in the assay.
Preparation of the recombinant catalytic domain of human neutrophil collagenase
(cdMMP-8): The enzyme was expressed in E. coli as an active variant.94
Preparation of PMNL-gelatinase (MMP-9): Latent PMNL-pro-gelatinase was prepared
from human plasma buffy coat as described by Tschesche et al.95 PMNL-pro-gelatinase
was activated prior to use by incubation with trypsin at 37°C for 10 min. Inactivation of
trypsin was accomplished with TKI.
Preparation of the recombinant catalytic domain of human macrophage elastase
(cdMMP-12): The catalytic domain of MMP-12 was expressed in E. coli. The over-
expressed protein was isolated as inclusion bodies, and the renatured protein was purified
by affinity column chromatography with an immobilized hydroxamate inhibitor.96
Preparation of the recombinant catalytic domain of human collagenase-3 (cdMMP-13):
Human pro-cdMMP-13 was prepared using an E. coli expression system.97 The isolated
pro-cdMMP-13 was activated prior to use by incubation with 5 mM HgCl2 for 2 h at 37°C.
Preparation of the recombinant catalytic domain of membrane-type-1 MMP (cdMMP-14):
The catalytic domain of MMP-14 was expressed in E. coli and was activated by
autocatalysis.98
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Preparation of the recombinant human ectodomain of membrane-type-1 MMP (MMP-14):
The ectodomain of MMP-14 was expressed in Pichia Pastoris by the method of Roderfeld
et al. and activated by yeast proteinases (furin-like proteinases) during maturation.99
6.4 Crystallography
6.4.1 Crystallization of the Inhibitors and Structure Analysis
Crystals of (2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)-
amino]propanamide 12b, (2S)-N-[5-(5-chloro-2-thienyl)-6H-1,3,4-thiadiazin-2-yl]-2-
[(phenylsulfonyl)amino]propanamide 13b, (2S)-N-[5-(4-chlorophenyl)-6H-1,3,4-thia-
diazin-2-yl]-2-[(2-thienylsulfonyl)amino]propanamide 14b, and (2R)-N-[5-(4-fluoro-
phenyl)-6H-1,3,4-thiadiazin-2-yl]-2-[(phenylsulfonyl)amino]propanamide 15a suitable for
diffraction analysis were obtained by slow crystallization in a Dewar environment from
solutions in methanol/acetonitrile (5 : 1).
All H atoms on N atoms in 12b, 14b and 15a were refined isotropically. Other H atoms in
12b, 14b and 15a, and all H atoms in 13b, were included in calculated positions using a
riding model, with U(H) = 1.2Ueq(C) for CH2 and CH groups, and U(H) = 1.5Ueq(C) for
CH3 groups, and C−H distances in the range 0.95−1.00 Å. The torsion angles of the CH3
groups were refined.
Data were collected under cryogenic conditions (100K) on the Siemens P2(1)
diffractometer (graphite monochromator, Mo−Kα radiation, λ = 0.71073 Å) with the
exception of compound 14b, which was examined on the Nonius Kappa CCD station (see
below). For all other compounds, data collection: P3/VMS100. Cell refinement: P3/VMS.
Data reduction: SHELXTL-Plus101. Program used to solve the structures: SHELXS-97102.
Program used to refine the structures: SHELXL-97103. Program for molecular graphics:
ORTEP-III104.
Crystals of N-allyl-5-(4-chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide 16
suitable for diffraction analysis were obtained by slow crystallization in a Dewar
environment from an ethanol/ethylacetate (1 : 3) solution.
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All H atoms in 16, were included in calculated positions using a riding model, with
U(H) = 1.2Ueq(C) for CH2 and CH groups, and C−H distances in the range 0.95−1.00 Å.
The H atoms on endocyclic N atoms were calculated as half occupied.
Diffraction data were collected under cryogenic conditions (100K) on the Nonius Kappa
CCD station. All calculations were performed using maXus.105 Data reduction: Denzo and
Scalepak.106 Program used to solve the structure: SHELXS-97. Program used to refine the
structure: SHELXL-97. Program for molecular graphic: ORTEP-III. Ring puckering
parameters were calculated using the program PLATON.107
6.4.2 Crystallization of the cdMMP-8/Inhibitor Complex and Structure Analysis
The catalytic domain of human neutrophil collagenase (cdMMP-8) was concentrated to
8 mg/mL and then mixed with 3-fold molar excess of an aqueous solution of N-allyl-5-(4-
chlorophenyl)-6H-1,3,4-thiadiazin-2-amine hydrobromide for a final cdMMP-8
concentration of 6 mg/mL. Three microliter of protein/inhibitor complex were mixed with
2 µL precipitant solution containing 100 mM cacodylate pH 5.5−6.5, 10 mM CaCl2,
100 mM NaCl, and 10% PEG 6000. The hanging drop was equilibrated by vapor diffusion
at 22°C against a reservoir containing 1.0−1.5 M phosphate buffer. The obtained crystals
belong to the orthorhombic space group P212121, and exhibit lattice constants a = 33.67 Å,
b = 69.64 Å, c = 73.40 Å, α = β = γ = 90°. The asymmetric unit contains one monomer.
X-ray data were collected on an imaging plate detector (MAR Research, Hamburg) to
2.7 Å resolution and processed using CCP4 data reduction software yielding an agreement
of redundant measurements of Rmerge = 9.3% over all data and 41% in the outer resolution
shell (completeness 98% and 87%, respectively). The orientation and translation of the
molecule within the crystallographic unit cell was determined with Patterson search
techniques108-110 using the program AMoRe.111 Electron density calculation and model
building proceeded using the program MAIN.112 The structure was refined using the
program X-PLOR to a crystallographic R-value of 21.1% (Rfree = 29.6%) with bond
deviations of 1.7° from ideally.113
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Ring puckering parameters of the complexed inhibitor were calculated using the program
PLATON. Atomic coordinates of the complex have been deposited in the Protein Data
Bank under accession code 1JH1.
6.5 Computational Docking and Modeling
The following steps preprocessed the ligand for docking experiments. First, the
coordinates of the reference compound 16 were extracted from the PDB file and
transformed into SYBYL mol2 file format. The res file format of the crystallographic data
of compound 14b were transformed to SYBYL mol2 file format using BABEL.114 The
two structures were loaded into the visualisation tool InsightII and modified by combining
the N-sulfonylated amino acid moiety from the X-ray structure of 14b with the
5-(4-chlorophenyl)-6H-1,3,4-thiadiazine-2-amine moiety from the PDB file. The "new"
inhibitor structure of 14b now provided reference coordinates to cdMMP-8. Correct atom
types including hybridization states (mol2 notation)115 as well as correct bond types were
defined. Hydrogen atoms were added to all atoms with reasonable geometries and formal
charges were assigned. The ligand was centered and an energy minimization was
performed using the command "Optimize".
For the receptor (cdMMP-8), a so-called receptor description file (rdf) was edited. The file
contains information on chains, substructures and hetero atoms to consider, on how to
resolve ambiguities in the PDB file (alternate location indicators), on how to add
hydrogens to polar atoms in the active site of cdMMP-8, etc. A template that contains
physico-chemical information about the amino acids was assigned to each amino acid of
cdMMP-8. All assignments were made according to default rules.
The docking package FlexX (GMD-SCAI, Germany) was used under standard conditions
(autodock mode) in combination with the molecule visualization program InsightII version
98' (MSI, Germany).
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6.6 In vitro Assays
6.6.1 MMP Inhibition Assay
Enzymatic activity was measured using a modified version of a resonance energy transfer
fluorogenic assay.116 Progress curves were monitored by following the increase in
fluorescence at 393 nm (λex = 328 nm), induced by the cleavage of the
(7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitro-phenyl]-L-2,3-diamino-
propionyl)-Ala-Arg-NH2 (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) fluorogenic substrate
by MMPs. Enzyme inhibition assays were carried out in MRB which consisted of 50 mM
HEPES/NaOH, pH 7.0, 10 mM CaCl2 and 0.02% (w/v) PEG 8000 at 25°C. MMP
microfluorometric profiling assay was done in white U-bottomed 96-well plates
(Microfluor 1 White, Dynex, USA) with a final substrate concentration of 6 µM
Mca-peptide, approximately 0.3 to 5 nM MMP with variable inhibitor concentrations and
2% DMSO vehicle. From a 1.5 mM stock (100% DMSO) the inhibitors were serially
diluted with MRB to 15, 10, 5, 3, 1, 0.6, 0.3, 0.1, 0.05, 0.01 and 0.005 µM final assay
concentration. Column 1, rows A through H, contained only DMSO for the "enzyme-only"
wells in the assay. After preincubation for 30 min at 25°C the reaction was started by
addition of substrate, and the plate was read on a SpectraFluor Plus (Tecan, Germany)
plate reader with excitation at 330 nm and emission at 405 nm with the gain set to 150.
Each measurement was done in triplicate to ensure statistically significant results. The
experiment was further controlled for background fluorescence of the substrate, for
fluorescence of fully cleaved substrate and for fluorescence quenching or augmentation
from solutions containing the test compounds.
6.6.2 Determination of the Ki -Values
Datapoints from eight different MMPs generated on the SpectraFluor Plus were directly
visualized on a master Excel spreadsheet. The response of inhibition was determined for
each inhibitor concentration by comparing the amount of hydrolysis (fluorescence units
generated over 30 minutes of hydrolysis) of wells containing compound with the "enzyme-
only" wells in column 1. With the program GraFit (Erithacus Software Limited) a
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4 parameter logistic fit to the dose-response data was used to calculate IC50 values for each
compound.
For each MMP, initial rate measurements in the absence of inhibitor were made for eight
different substrate concentrations. From these data, Km values were determined by non-
linear fit using the program GraFit. The Km values determined for MMP-1, cdMMP-2,
cdMMP-8, MMP-9, cdMMP-12, cdMMP-13, cdMMP-14 and the ectodomain of MMP-14
were 40.3, 9.1, 5.9, 1.8, 27.3, 7.5, 6.8, and 7.5 µM. Evaluation of the kinetic data was
performed as reported by Copeland et al. and Horovitz & Levitzki.117,118 Assuming
Michaelis-Menten kinetics, the Ki-values were calculated using the equation:
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Table 1.  Crystal data and structure refinement for compound 14b.
      Identification code               14b
      Measurement device                Nonius KappaCCD
      Empirical formula                 C16 H15 Cl N4 O3 S3 + 0.25 CH3OH
      Formula weight                    450.96
      Temperature                       100(2) K
      Wavelength                        0.71073 A
      Crystal system, space group       Tetragonal P 41 21 2
      Unit cell dimensions              a = 10.0460(4) A   alpha = 90.000(3) deg.
                                        b = 10.046(2)  A    beta = 90.000(4) deg.
                                        c = 74.8620(4) A   gamma = 90.000(3) deg.
      Volume                            7555.2(18) A^3
      Z, Calculated density             16,  1.586 Mg/m^3
      Absorption coefficient            0.562 mm^-1
      F(000)                            3720
      Crystal size, colour and habit    0.27 x 0.21 x 0.07 mm^3, Colorless plates
      Theta range for data collection   2.05 to 24.99 deg.
      Index ranges                      -11<=h<=11, -11<=k<=11, -89<=l<=88
      Reflections collected / unique    33232 / 6252 [R(int) = 0.0763]
      Completeness to theta = 24.99     97.2%
      Absorption correction             Semi-empirical from equivalents
      Max. and min. transmission        1.067 and 0.962
      Refinement method                 Full-matrix least-squares on F^2
      Data / restraints / parameters    6252 / 0 / 515
      Goodness-of-fit on F^2            1.123
      Final R indices [I>2sigma(I)]     R1 = 0.0562, wR2 = 0.0863 [5215]
      R indices (all data)              R1 = 0.0789, wR2 = 0.0925
      Absolute structure parameter      0.02(8)
      Largest diff. peak and hole       0.376 and -0.370 e.A^-3
      remarks                           Hydrogens of CH3OH were not included.
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         Table 2. Atomic coordinates ( x 10^4) and equivalent isotropic
         displacement parameters (A^2 x 10^3) for 14b.
         U(eq) is defined as one third of the trace of the orthogonalized
         Uij tensor.
         ________________________________________________________________
                         x             y             z           U(eq)
         ________________________________________________________________
          Cl(1)       28873(1)      13213(1)        515(1)       29(1)
          S(1)        23250(1)       8585(1)       1038(1)       17(1)
          S(2)        17747(1)       8244(1)       1132(1)       19(1)
          S(3)        19893(1)      10150(1)       1245(1)       32(1)
          O(1)        21721(3)       6574(3)       1143(1)       22(1)
          O(2)        16464(3)       8567(3)       1060(1)       26(1)
          O(3)        17910(3)       7931(3)       1316(1)       24(1)
          N(1)        23345(4)       9640(4)        658(1)       19(1)
          N(2)        22169(4)       8998(4)        715(1)       17(1)
          N(3)        20953(4)       7644(4)        895(1)       15(1)
          N(4)        18284(4)       7006(4)       1017(1)       17(1)
          C(1)        25834(4)      10657(5)        540(1)       18(1)
          C(2)        26933(4)      11367(5)        478(1)       19(1)
          C(3)        27468(4)      12335(5)        586(1)       19(1)
          C(4)        26943(5)      12629(5)        752(1)       21(1)
          C(5)        25858(4)      11907(4)        811(1)       15(1)
          C(6)        25296(4)      10915(4)        707(1)       12(1)
          C(7)        24100(4)      10195(4)        773(1)       13(1)
          C(8)        23798(5)      10206(4)        967(1)       17(1)
          C(9)        22073(4)       8414(4)        869(1)       13(1)
          C(10)       20797(4)       6857(5)       1041(1)       16(1)
          C(11)       19436(4)       6239(4)       1071(1)       15(1)
          C(12)       19413(5)       4877(5)        979(1)       23(1)
          C(13)       18784(4)       9607(5)       1088(1)       20(1)
          C(14)       18835(4)      10295(4)        928(1)       14(1)
          C(15)       19860(5)      11296(5)        941(1)       24(1)
          C(16)       20468(5)      11321(5)       1102(1)       27(1)
          Cl(2)       12435(1)       3414(1)        770(1)       26(1)
          S(4)        17997(1)       8360(1)        266(1)       18(1)
          S(5)        23323(1)       8339(1)         94(1)       20(1)
          S(6)        21194(1)       6260(1)         51(1)       29(1)
          O(4)        19676(3)      10433(3)        192(1)       21(1)
          O(5)        24403(3)       8544(3)        215(1)       25(1)
          O(6)        23569(3)       8027(3)        -89(1)       23(1)
          N(5)        17785(4)       7135(4)        635(1)       18(1)
          N(6)        18981(4)       7773(4)        591(1)       19(1)
          N(7)        20289(4)       9136(4)        428(1)       16(1)
          N(8)        22431(4)       9684(4)         93(1)       18(1)
          C(17)       15189(4)       6266(5)        731(1)       16(1)
          C(18)       14114(4)       5506(5)        791(1)       17(1)
          C(19)       13728(4)       4414(4)        692(1)       17(1)
          C(20)       14340(4)       4091(4)        534(1)       18(1)
          C(21)       15384(4)       4863(5)        473(1)       19(1)
          C(22)       15823(4)       5939(4)        573(1)       16(1)
          C(23)       17036(4)       6656(4)        513(1)       13(1)
          C(24)       17375(4)       6720(5)        320(1)       17(1)
          C(25)       19121(4)       8427(4)        443(1)       15(1)
          C(26)       20554(5)       9980(4)        290(1)       15(1)
          C(27)       22017(4)      10311(5)        261(1)       18(1)
          C(28)       22254(5)      11804(5)        257(1)       24(1)
          C(29)       22356(4)       7056(4)        182(1)       18(1)
          C(30)       22369(4)       6611(4)        354(1)       17(1)
          C(31)       21400(5)       5597(5)        379(1)       22(1)
          C(32)       20715(5)       5306(5)        227(1)       23(1)
          O(7)        25426(5)      15426(5)          0         128(4)
          C(33)       24410(6)      14410(6)          0          68(3)
         ________________________________________________________________
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           Table 3.  Bond lengths [A] and angles [deg] for 14b.
           _____________________________________________________________
            Cl(1)-C(3)                    1.748(4)
            S(1)-C(9)                     1.742(4)
            S(1)-C(8)                     1.800(5)
            S(2)-O(3)                     1.423(3)
            S(2)-O(2)                     1.432(3)
            S(2)-N(4)                     1.605(4)
            S(2)-C(13)                    1.750(5)
            S(3)-C(16)                    1.689(5)
            S(3)-C(13)                    1.707(5)
            O(1)-C(10)                    1.232(5)
            N(1)-C(7)                     1.275(5)
            N(1)-N(2)                     1.412(5)
            N(2)-C(9)                     1.298(5)
            N(3)-C(10)                    1.361(6)
            N(3)-C(9)                     1.379(5)
            N(3)-H(3)                     1.03(5)
            N(4)-C(11)                    1.449(6)
            N(4)-H(4)                     0.86(4)
            C(1)-C(6)                     1.389(6)
            C(1)-C(2)                     1.394(6)
            C(2)-C(3)                     1.378(6)
            C(3)-C(4)                     1.379(6)
            C(4)-C(5)                     1.383(6)
            C(5)-C(6)                     1.388(6)
            C(6)-C(7)                     1.487(6)
            C(7)-C(8)                     1.486(6)
            C(10)-C(11)                   1.517(6)
            C(11)-C(12)                   1.533(6)
            C(13)-C(14)                   1.387(6)
            C(14)-C(15)                   1.442(6)
            C(15)-C(16)                   1.352(6)
            Cl(2)-C(19)                   1.744(4)
            S(4)-C(25)                    1.746(4)
            S(4)-C(24)                    1.810(5)
            S(5)-O(5)                     1.427(3)
            S(5)-O(6)                     1.429(3)
            S(5)-N(8)                     1.621(4)
            S(5)-C(29)                    1.744(4)
            S(6)-C(32)                    1.702(5)
            S(6)-C(29)                    1.724(4)
            O(4)-C(26)                    1.236(5)
            N(5)-C(23)                    1.279(5)
            N(5)-N(6)                     1.400(5)
            N(6)-C(25)                    1.298(5)
            N(7)-C(26)                    1.358(5)
            N(7)-C(25)                    1.377(6)
            N(7)-H(7)                     1.00(6)
            N(8)-C(27)                    1.470(6)
            N(8)-H(8)                     0.76(5)
            C(17)-C(22)                   1.385(6)
            C(17)-C(18)                   1.395(6)
            C(18)-C(19)                   1.379(6)
            C(19)-C(20)                   1.372(6)
            C(20)-C(21)                   1.382(6)
            C(21)-C(22)                   1.387(6)
            C(22)-C(23)                   1.485(6)
            C(23)-C(24)                   1.484(6)
            C(26)-C(27)                   1.523(6)
            C(27)-C(28)                   1.519(6)
            C(29)-C(30)                   1.363(6)
            C(30)-C(31)                   1.421(6)
            C(31)-C(32)                   1.362(6)
            O(7)-C(33)                    1.444(11)
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            C(9)-S(1)-C(8)               94.7(2)
            O(3)-S(2)-O(2)              120.99(19)
            O(3)-S(2)-N(4)              107.9(2)
            O(2)-S(2)-N(4)              106.19(19)
            O(3)-S(2)-C(13)             106.5(2)
            O(2)-S(2)-C(13)             106.8(2)
            N(4)-S(2)-C(13)             107.9(2)
            C(16)-S(3)-C(13)             90.7(2)
            C(7)-N(1)-N(2)              119.5(4)
            C(9)-N(2)-N(1)              122.5(4)
            C(10)-N(3)-C(9)             122.2(4)
            C(10)-N(3)-H(3)             124(3)
            C(9)-N(3)-H(3)              114(3)
            C(11)-N(4)-S(2)             122.1(3)
            C(11)-N(4)-H(4)             118(3)
            S(2)-N(4)-H(4)              115(3)
            C(6)-C(1)-C(2)              120.9(4)
            C(3)-C(2)-C(1)              118.2(4)
            C(2)-C(3)-C(4)              122.3(4)
            C(2)-C(3)-Cl(1)             119.4(3)
            C(4)-C(3)-Cl(1)             118.4(4)
            C(3)-C(4)-C(5)              118.6(4)
            C(4)-C(5)-C(6)              121.0(4)
            C(5)-C(6)-C(1)              119.0(4)
            C(5)-C(6)-C(7)              119.4(4)
            C(1)-C(6)-C(7)              121.6(4)
            N(1)-C(7)-C(8)              122.9(4)
            N(1)-C(7)-C(6)              117.9(4)
            C(8)-C(7)-C(6)              119.1(4)
            C(7)-C(8)-S(1)              110.2(3)
            N(2)-C(9)-N(3)              116.1(4)
            N(2)-C(9)-S(1)              123.5(3)
            N(3)-C(9)-S(1)              120.4(3)
            O(1)-C(10)-N(3)             122.9(4)
            O(1)-C(10)-C(11)            119.6(4)
            N(3)-C(10)-C(11)            117.3(4)
            N(4)-C(11)-C(10)            117.5(4)
            N(4)-C(11)-C(12)            109.7(4)
            C(10)-C(11)-C(12)           108.2(4)
            C(14)-C(13)-S(3)            114.3(4)
            C(14)-C(13)-S(2)            124.9(3)
            S(3)-C(13)-S(2)             120.8(3)
            C(13)-C(14)-C(15)           108.3(4)
            C(16)-C(15)-C(14)           113.4(4)
            C(15)-C(16)-S(3)            113.3(4)
            C(25)-S(4)-C(24)             94.9(2)
            O(5)-S(5)-O(6)              120.6(2)
            O(5)-S(5)-N(8)              107.7(2)
            O(6)-S(5)-N(8)              105.8(2)
            O(5)-S(5)-C(29)             106.88(19)
            O(6)-S(5)-C(29)             107.3(2)
            N(8)-S(5)-C(29)             108.1(2)
            C(32)-S(6)-C(29)             90.5(2)
            C(23)-N(5)-N(6)             120.6(4)
            C(25)-N(6)-N(5)             121.7(4)
            C(26)-N(7)-C(25)            123.6(4)
            C(26)-N(7)-H(7)             122(4)
            C(25)-N(7)-H(7)             114(4)
            C(27)-N(8)-S(5)             120.5(3)
            C(27)-N(8)-H(8)             128(4)
            S(5)-N(8)-H(8)              103(4)
            C(22)-C(17)-C(18)           120.0(4)
            C(19)-C(18)-C(17)           118.8(4)
            C(20)-C(19)-C(18)           121.6(4)
            C(20)-C(19)-Cl(2)           119.2(3)
            C(18)-C(19)-Cl(2)           119.2(4)
            C(19)-C(20)-C(21)           119.5(4)
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            C(20)-C(21)-C(22)           120.0(4)
            C(17)-C(22)-C(21)           120.0(4)
            C(17)-C(22)-C(23)           121.4(4)
            C(21)-C(22)-C(23)           118.5(4)
            N(5)-C(23)-C(24)            123.0(4)
            N(5)-C(23)-C(22)            116.7(4)
            C(24)-C(23)-C(22)           120.1(4)
            C(23)-C(24)-S(4)            109.8(3)
            N(6)-C(25)-N(7)             115.3(4)
            N(6)-C(25)-S(4)             124.2(3)
            N(7)-C(25)-S(4)             120.4(3)
            O(4)-C(26)-N(7)             122.7(4)
            O(4)-C(26)-C(27)            121.5(4)
            N(7)-C(26)-C(27)            115.8(4)
            N(8)-C(27)-C(28)            111.2(4)
            N(8)-C(27)-C(26)            107.7(4)
            C(28)-C(27)-C(26)           111.7(4)
            C(30)-C(29)-S(6)            113.2(3)
            C(30)-C(29)-S(5)            126.5(3)
            S(6)-C(29)-S(5)             120.3(2)
            C(29)-C(30)-C(31)           110.7(4)
            C(32)-C(31)-C(30)           112.9(4)
            C(31)-C(32)-S(6)            112.7(4)
           _____________________________________________________________
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         Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 14b.
         The anisotropic displacement factor exponent takes the form:
         -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]
_______________________________________________________________________
U11        U22        U33        U23        U13        U12
_______________________________________________________________________
Cl(1)    22(1)      39(1)      26(1)       3(1)       2(1)     -21(1)
S(1)     14(1)      19(1)      18(1)       4(1)      -3(1)      -5(1)
S(2)     13(1)      23(1)      21(1)       2(1)       1(1)       1(1)
S(3)     26(1)      38(1)      30(1)      -7(1)      -9(1)       2(1)
O(1)     16(2)      23(2)      28(2)       6(2)      -5(2)       0(2)
O(2)      5(2)      31(2)      41(2)       9(2)       1(2)       0(2)
O(3)     21(2)      32(2)      18(2)       2(2)       5(1)       6(2)
N(1)     12(2)      23(2)      20(2)       5(2)       2(2)      -5(2)
N(2)     12(2)      22(2)      19(2)       7(2)       2(2)      -5(2)
N(3)     12(2)      17(2)      16(2)       4(2)       1(2)      -5(2)
N(4)     12(2)      26(2)      13(2)       3(2)      -2(2)      -4(2)
C(1)     18(3)      13(3)      23(3)       0(2)      -4(2)      -3(2)
C(2)     13(3)      23(3)      21(2)       2(2)      -1(2)       1(2)
C(3)     10(3)      20(3)      27(3)       6(2)      -2(2)      -8(2)
C(4)     21(3)      23(3)      20(2)      -1(2)      -6(2)      -7(2)
C(5)     14(3)      15(3)      16(2)       0(2)       0(2)      -2(2)
C(6)      9(2)      14(3)      15(2)       1(2)      -4(2)       2(2)
C(7)     12(3)      11(2)      17(2)      -3(2)      -1(2)       1(2)
C(8)     19(3)      15(3)      18(2)      -3(2)       2(2)      -5(2)
C(9)     11(3)      16(3)      11(2)      -2(2)       0(2)      -2(2)
C(10)    10(3)      12(3)      28(3)      -4(2)       3(2)      -1(2)
C(11)    15(3)      17(3)      13(2)       5(2)      -1(2)       0(2)
C(12)    20(3)      17(3)      33(3)      -1(2)       3(2)      -7(2)
C(13)    12(3)      23(3)      26(3)      -6(2)      -1(2)       1(2)
C(14)    11(2)       6(2)      25(3)       2(2)       2(2)       1(2)
C(15)    19(3)      15(3)      37(3)       1(2)       2(2)       0(2)
C(16)    14(3)      21(3)      46(3)      -7(3)      -2(3)      -1(2)
Cl(2)    16(1)      24(1)      37(1)       7(1)       3(1)      -7(1)
S(4)     16(1)      19(1)      18(1)       4(1)      -4(1)      -6(1)
S(5)     14(1)      20(1)      26(1)       7(1)      -3(1)      -6(1)
S(6)     26(1)      31(1)      30(1)       5(1)      -6(1)     -14(1)
O(4)     18(2)      22(2)      23(2)       8(2)      -4(2)      -7(2)
O(5)     18(2)      23(2)      35(2)       5(2)      -9(2)      -7(2)
O(6)     20(2)      22(2)      27(2)       3(2)       6(2)      -3(2)
N(5)     13(2)      20(2)      20(2)       1(2)       1(2)      -6(2)
N(6)     10(2)      20(2)      25(2)       8(2)      -2(2)      -7(2)
N(7)     10(2)      22(2)      14(2)       4(2)      -2(2)      -6(2)
N(8)     16(2)      20(2)      17(2)       6(2)      -6(2)      -5(2)
C(17)    11(3)      18(3)      19(2)      -1(2)      -4(2)      -2(2)
C(18)     9(3)      23(3)      21(2)       3(2)       1(2)       0(2)
C(19)     8(3)      16(3)      26(3)       9(2)      -5(2)      -3(2)
C(20)    14(3)      17(3)      24(3)       0(2)      -5(2)      -7(2)
C(21)    11(3)      23(3)      22(2)       2(2)       1(2)      -2(2)
C(22)     9(3)      16(3)      24(3)       5(2)      -7(2)      -3(2)
C(23)    15(3)       9(2)      16(2)      -3(2)      -5(2)       3(2)
C(24)    12(2)      18(3)      22(2)      -1(2)       1(2)      -5(2)
C(25)    14(3)      14(3)      16(2)      -1(2)       1(2)      -2(2)
C(26)    18(3)      16(3)      12(2)       0(2)      -4(2)      -6(2)
C(27)    17(3)      24(3)      12(2)       4(2)      -7(2)     -12(2)
C(28)    19(3)      22(3)      29(3)       0(2)       1(2)     -10(2)
C(29)    15(3)      18(3)      20(2)       4(2)      -6(2)      -6(2)
C(30)    11(2)      13(3)      28(3)       0(2)       4(2)      -3(2)
C(31)    20(3)      21(3)      26(3)       7(2)       5(2)       1(2)
C(32)    20(3)      17(3)      32(3)       3(2)      -2(2)      -3(2)
O(7)    156(6)     156(6)      72(5)     -40(5)      40(5)    -108(7)
C(33)    50(4)      50(4)     105(8)      -3(4)       3(4)     -23(5)
_______________________________________________________________________
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic
         displacement parameters (A^2 x 10^3) for 14b.
         ________________________________________________________________
                         x             y             z           U(eq)
         ________________________________________________________________
          H(3)        20260(5)       7730(5)        794(6)       47(16)
          H(4)        18090(4)       7020(4)        905(5)        9(12)
          H(1A)       25448          9988           466          22
          H(2A)       27304         11188           363          23
          H(4A)       27320         13312           824          26
          H(5A)       25491         12094           926          18
          H(8A)       23095         10871           992          21
          H(8B)       24605         10464          1035          21
          H(11)       19348          6074          1202          18
          H(12A)      18592          4407          1011          35
          H(12B)      20183          4353          1018          35
          H(12C)      19449          4999           849          35
          H(14)       18289         10135           826          17
          H(15)       20085         11880           846          28
          H(16)       21151         11935          1132          32
          H(7)        20940(6)       8980(6)        527(8)       80(2)
          H(8)        22040(5)       9630(5)          5(6)       30(18)
          H(17)       15485          7006           799          20
          H(18)       13657          5738           897          21
          H(20)       14048          3342           467          22
          H(21)       15801          4657           362          22
          H(24A)      16573          6525           248          21
          H(24B)      18059          6043           292          21
          H(27)       22548          9917           361          21
          H(28A)      23196         11980           232          35
          H(28B)      22013         12189           373          35
          H(28C)      21706         12206           163          35
          H(30)       22947          6933           445          21
          H(31)       21247          5168           490          27
          H(32)       20042          4643           221          27
         ________________________________________________________________
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      Table 1.  Crystal data and structure refinement for 16.
      Identification code               16
      Measurement device                Nonius KappaCCD
      Empirical formula                 C12 H13 Br Cl N3 S
      Formula weight                    346.67
      Temperature                       100(2) K
      Wavelength                        0.71073 A
      Crystal system, space group       Monoclinic P 21/c
      Unit cell dimensions              a = 21.3350(6) A   alpha = 90.0000(17)  deg.
                                        b = 9.3150(2)  A    beta = 102.9950(19) deg.
                                        c = 14.4910(4) A   gamma = 90.000(3)    deg.
      Volume                            2806.12(13) A^3
      Z, Calculated density             8,  1.641 Mg/m^3
      Absorption coefficient            3.254 mm^-1
      F(000)                            1392
      Crystal size, colour and habit    0.50 x 0.30 x 0.30 mm^3, Colorless Irregular
      Theta range for data collection   2.40 to 30.00 deg.
      Index ranges                      -30<=h<=30, -13<=k<=13, -20<=l<=19
      Reflections collected / unique    51635 / 8102 [R(int) = 0.0615]
      Completeness to theta = 30.00     93.7%
      Absorption correction             Semi-empirical from equivalents
      Max. and min. transmission        0.4418 and 0.2930
      Refinement method                 Full-matrix least-squares on F^2
      Data / restraints / parameters    8102 / 0 / 325
      Goodness-of-fit on F^2            1.037
      Final R indices [I>2sigma(I)]     R1 = 0.0456, wR2 = 0.0813 [6357]
      R indices (all data)              R1 = 0.0699, wR2 = 0.0881
      Largest diff. peak and hole       1.033 and -0.702 e.A^-3
      remarks                           H(1A), H(2A), H(4A) and H(5A) were
                                        calculated as half occupied.
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic
         displacement parameters (A^2 x 10^3) for 16.
         U(eq) is defined as one third of the trace of the orthogonalized
         Uij tensor.
         ________________________________________________________________
                         x             y             z           U(eq)
         ________________________________________________________________
          Br(1)        4541(1)       7176(1)       3717(1)       17(1)
          Br(2)         515(1)       2159(1)       1189(1)       19(1)
          S(1)         4957(1)       1390(1)       3605(1)       17(1)
          S(2)          192(1)      -3664(1)       1315(1)       17(1)
          Cl(1)        1226(1)      -1311(1)       3396(1)       23(1)
          Cl(2)        3858(1)      -6581(1)       1485(1)       22(1)
          N(1)         3739(1)       3018(3)       3737(2)       16(1)
          N(2)         4326(1)       3734(3)       3901(2)       15(1)
          N(3)         5333(1)       4121(3)       3653(2)       20(1)
          N(4)         1405(1)      -2029(3)       1145(2)       17(1)
          N(5)          818(1)      -1307(3)       1009(2)       17(1)
          N(6)         -184(1)       -967(3)       1310(2)       19(1)
          C(1)         3103(1)       -490(3)       4100(2)       18(1)
          C(2)         2517(1)      -1174(3)       3988(2)       19(1)
          C(3)         1972(1)       -498(3)       3478(2)       19(1)
          C(4)         2001(1)        812(3)       3049(2)       21(1)
          C(5)         2590(1)       1498(3)       3172(2)       19(1)
          C(6)         3148(1)        863(3)       3713(2)       15(1)
          C(7)         3761(1)       1660(3)       3896(2)       16(1)
          C(8)         4386(1)        922(3)       4300(2)       16(1)
          C(9)         4873(1)       3218(3)       3732(2)       18(1)
          C(10)        5987(1)       3717(4)       3610(2)       25(1)
          C(11)        6473(2)       4258(4)       4429(2)       27(1)
          C(12)        7008(2)       4884(4)       4355(3)       43(1)
          C(13)        2007(1)      -5538(3)        714(2)       18(1)
          C(14)        2580(1)      -6281(3)        828(2)       20(1)
          C(15)        3132(1)      -5683(3)       1381(2)       17(1)
          C(16)        3119(1)      -4379(3)       1822(2)       19(1)
          C(17)        2549(1)      -3629(3)       1691(2)       18(1)
          C(18)        1980(1)      -4194(3)       1124(2)       16(1)
          C(19)        1373(1)      -3384(3)        968(2)       16(1)
          C(20)         747(1)      -4119(3)        585(2)       17(1)
          C(21)         272(1)      -1840(3)       1197(2)       16(1)
          C(22)        -831(1)      -1472(3)       1326(2)       22(1)
          C(23)       -1293(2)       -268(4)       1186(2)       27(1)
          C(24)       -1691(2)        -70(4)       1742(3)       30(1)
         ________________________________________________________________
Chapter 8   Appendix 97
           Table 3.  Bond lengths [A] and angles [deg] for 16.
           _____________________________________________________________
            S(1)-C(9)                     1.726(3)
            S(1)-C(8)                     1.801(3)
            S(2)-C(21)                    1.720(3)
            S(2)-C(20)                    1.805(3)
            Cl(1)-C(3)                    1.742(3)
            Cl(2)-C(15)                   1.739(3)
            N(1)-C(7)                     1.285(4)
            N(1)-N(2)                     1.392(3)
            N(1)-H(1A)                    0.8800
            N(2)-C(9)                     1.335(4)
            N(2)-H(2A)                    0.8800
            N(3)-C(9)                     1.316(4)
            N(3)-C(10)                    1.461(4)
            N(3)-H(3A)                    0.8800
            N(4)-C(19)                    1.287(4)
            N(4)-N(5)                     1.395(3)
            N(4)-H(4A)                    0.8800
            N(5)-C(21)                    1.349(4)
            N(5)-H(5A)                    0.8800
            N(6)-C(21)                    1.306(4)
            N(6)-C(22)                    1.465(4)
            N(6)-H(6A)                    0.8800
            C(1)-C(2)                     1.380(4)
            C(1)-C(6)                     1.391(4)
            C(1)-H(1B)                    0.9500
            C(2)-C(3)                     1.382(4)
            C(2)-H(2B)                    0.9500
            C(3)-C(4)                     1.377(4)
            C(4)-C(5)                     1.384(4)
            C(4)-H(4B)                    0.9500
            C(5)-C(6)                     1.401(4)
            C(5)-H(5B)                    0.9500
            C(6)-C(7)                     1.474(4)
            C(7)-C(8)                     1.498(4)
            C(8)-H(8A)                    0.9900
            C(8)-H(8B)                    0.9900
            C(10)-C(11)                   1.478(4)
            C(10)-H(10A)                  0.9900
            C(10)-H(10B)                  0.9900
            C(11)-C(12)                   1.307(5)
            C(11)-H(11A)                  0.9500
            C(12)-H(12A)                  0.9500
            C(12)-H(12B)                  0.9500
            C(13)-C(14)                   1.382(4)
            C(13)-C(18)                   1.392(4)
            C(13)-H(13A)                  0.9500
            C(14)-C(15)                   1.383(4)
            C(14)-H(14A)                  0.9500
            C(15)-C(16)                   1.375(4)
            C(16)-C(17)                   1.377(4)
            C(16)-H(16A)                  0.9500
            C(17)-C(18)                   1.406(4)
            C(17)-H(17A)                  0.9500
            C(18)-C(19)                   1.472(4)
            C(19)-C(20)                   1.493(4)
            C(20)-H(20A)                  0.9900
            C(20)-H(20B)                  0.9900
            C(22)-C(23)                   1.477(4)
            C(22)-H(22A)                  0.9900
            C(22)-H(22B)                  0.9900
            C(23)-C(24)                   1.308(4)
            C(23)-H(23A)                  0.9500
            C(24)-H(24A)                  0.9500
            C(24)-H(24B)                  0.9500
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            C(9)-S(1)-C(8)               94.55(14)
            C(21)-S(2)-C(20)             94.65(13)
            C(7)-N(1)-N(2)              116.6(2)
            C(7)-N(1)-H(1A)             121.7
            N(2)-N(1)-H(1A)             121.7
            C(9)-N(2)-N(1)              125.9(2)
            C(9)-N(2)-H(2A)             117.1
            N(1)-N(2)-H(2A)             117.1
            C(9)-N(3)-C(10)             125.2(3)
            C(9)-N(3)-H(3A)             117.4
            C(10)-N(3)-H(3A)            117.4
            C(19)-N(4)-N(5)             116.0(2)
            C(19)-N(4)-H(4A)            122.0
            N(5)-N(4)-H(4A)             122.0
            C(21)-N(5)-N(4)             125.6(2)
            C(21)-N(5)-H(5A)            117.2
            N(4)-N(5)-H(5A)             117.2
            C(21)-N(6)-C(22)            122.2(3)
            C(21)-N(6)-H(6A)            118.9
            C(22)-N(6)-H(6A)            118.9
            C(2)-C(1)-C(6)              120.9(3)
            C(2)-C(1)-H(1B)             119.6
            C(6)-C(1)-H(1B)             119.6
            C(1)-C(2)-C(3)              119.0(3)
            C(1)-C(2)-H(2B)             120.5
            C(3)-C(2)-H(2B)             120.5
            C(4)-C(3)-C(2)              121.7(3)
            C(4)-C(3)-Cl(1)             119.2(2)
            C(2)-C(3)-Cl(1)             119.0(2)
            C(3)-C(4)-C(5)              118.9(3)
            C(3)-C(4)-H(4B)             120.6
            C(5)-C(4)-H(4B)             120.6
            C(4)-C(5)-C(6)              120.6(3)
            C(4)-C(5)-H(5B)             119.7
            C(6)-C(5)-H(5B)             119.7
            C(1)-C(6)-C(5)              118.8(3)
            C(1)-C(6)-C(7)              121.5(3)
            C(5)-C(6)-C(7)              119.7(3)
            N(1)-C(7)-C(6)              118.0(2)
            N(1)-C(7)-C(8)              121.0(3)
            C(6)-C(7)-C(8)              121.0(2)
            C(7)-C(8)-S(1)              109.00(19)
            C(7)-C(8)-H(8A)             109.9
            S(1)-C(8)-H(8A)             109.9
            C(7)-C(8)-H(8B)             109.9
            S(1)-C(8)-H(8B)             109.9
            H(8A)-C(8)-H(8B)            108.3
            N(3)-C(9)-N(2)              119.0(3)
            N(3)-C(9)-S(1)              121.6(2)
            N(2)-C(9)-S(1)              119.4(2)
            N(3)-C(10)-C(11)            112.5(3)
            N(3)-C(10)-H(10A)           109.1
            C(11)-C(10)-H(10A)          109.1
            N(3)-C(10)-H(10B)           109.1
            C(11)-C(10)-H(10B)          109.1
            H(10A)-C(10)-H(10B)         107.8
            C(12)-C(11)-C(10)           123.7(3)
            C(12)-C(11)-H(11A)          118.2
            C(10)-C(11)-H(11A)          118.2
            C(11)-C(12)-H(12A)          120.0
            C(11)-C(12)-H(12B)          120.0
            H(12A)-C(12)-H(12B)         120.0
            C(14)-C(13)-C(18)           121.2(3)
            C(14)-C(13)-H(13A)          119.4
            C(18)-C(13)-H(13A)          119.4
            C(13)-C(14)-C(15)           118.9(3)
            C(13)-C(14)-H(14A)          120.6
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            C(15)-C(14)-H(14A)          120.6
            C(16)-C(15)-C(14)           121.4(3)
            C(16)-C(15)-Cl(2)           119.7(2)
            C(14)-C(15)-Cl(2)           118.9(2)
            C(15)-C(16)-C(17)           119.5(3)
            C(15)-C(16)-H(16A)          120.2
            C(17)-C(16)-H(16A)          120.2
            C(16)-C(17)-C(18)           120.7(3)
            C(16)-C(17)-H(17A)          119.7
            C(18)-C(17)-H(17A)          119.7
            C(13)-C(18)-C(17)           118.3(3)
            C(13)-C(18)-C(19)           120.9(3)
            C(17)-C(18)-C(19)           120.8(3)
            N(4)-C(19)-C(18)            117.9(3)
            N(4)-C(19)-C(20)            121.8(3)
            C(18)-C(19)-C(20)           120.3(2)
            C(19)-C(20)-S(2)            108.92(19)
            C(19)-C(20)-H(20A)          109.9
            S(2)-C(20)-H(20A)           109.9
            C(19)-C(20)-H(20B)          109.9
            S(2)-C(20)-H(20B)           109.9
            H(20A)-C(20)-H(20B)         108.3
            N(6)-C(21)-N(5)             119.8(3)
            N(6)-C(21)-S(2)             120.6(2)
            N(5)-C(21)-S(2)             119.5(2)
            N(6)-C(22)-C(23)            110.9(3)
            N(6)-C(22)-H(22A)           109.5
            C(23)-C(22)-H(22A)          109.5
            N(6)-C(22)-H(22B)           109.5
            C(23)-C(22)-H(22B)          109.5
            H(22A)-C(22)-H(22B)         108.0
            C(24)-C(23)-C(22)           121.9(3)
            C(24)-C(23)-H(23A)          119.0
            C(22)-C(23)-H(23A)          119.0
            C(23)-C(24)-H(24A)          120.0
            C(23)-C(24)-H(24B)          120.0
            H(24A)-C(24)-H(24B)         120.0
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        Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 16.
        The anisotropic displacement factor exponent takes the form:
        -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]
_______________________________________________________________________
U11        U22        U33        U23        U13        U12
_______________________________________________________________________
Br(1)    19(1)      12(1)      17(1)      -2(1)       0(1)       0(1)
Br(2)    24(1)      12(1)      18(1)       2(1)      -3(1)      -3(1)
S(1)     17(1)      14(1)      20(1)      -2(1)       4(1)       5(1)
S(2)     17(1)      13(1)      20(1)       2(1)       1(1)      -3(1)
Cl(1)    18(1)      29(1)      21(1)      -2(1)       3(1)      -4(1)
Cl(2)    18(1)      28(1)      21(1)       3(1)       3(1)       2(1)
N(1)     16(1)      14(1)      17(1)       1(1)       2(1)       2(1)
N(2)     14(1)      14(1)      18(1)      -3(1)       4(1)       2(1)
N(3)     16(1)      16(1)      28(1)      -4(1)       5(1)       1(1)
N(4)     18(1)      15(1)      16(1)       0(1)       2(1)      -2(1)
N(5)     19(1)      13(1)      18(1)       1(1)       3(1)      -3(1)
N(6)     20(1)      15(1)      20(1)      -2(1)       2(1)      -4(1)
C(1)     19(1)      15(1)      19(1)       0(1)      -1(1)       5(1)
C(2)     23(1)      13(1)      19(1)       0(1)       3(1)      -1(1)
C(3)     15(1)      23(2)      17(1)      -5(1)       4(1)      -2(1)
C(4)     18(1)      23(2)      19(1)       2(1)       0(1)       5(1)
C(5)     21(1)      18(2)      18(1)       7(1)       2(1)       3(1)
C(6)     16(1)      15(1)      14(1)      -1(1)       2(1)       3(1)
C(7)     18(1)      15(1)      14(1)      -2(1)       3(1)       3(1)
C(8)     15(1)      14(1)      17(1)       1(1)      -1(1)       4(1)
C(9)     20(1)      18(1)      13(1)       0(1)       1(1)       6(1)
C(10)    16(1)      28(2)      32(2)     -10(1)       8(1)       1(1)
C(11)    25(2)      25(2)      29(2)      -2(1)       2(1)       7(1)
C(12)    35(2)      33(2)      56(3)      -2(2)      -2(2)      -7(2)
C(13)    18(1)      19(1)      16(1)      -1(1)       0(1)      -3(1)
C(14)    22(1)      18(1)      18(1)       1(1)       3(1)      -2(1)
C(15)    16(1)      20(1)      17(1)       7(1)       4(1)       0(1)
C(16)    16(1)      24(2)      15(1)       2(1)       2(1)      -6(1)
C(17)    22(1)      16(1)      17(1)      -1(1)       4(1)      -7(1)
C(18)    18(1)      19(1)      12(1)       2(1)       4(1)      -2(1)
C(19)    19(1)      14(1)      12(1)       0(1)       0(1)      -6(1)
C(20)    18(1)      14(1)      19(1)      -1(1)       2(1)      -2(1)
C(21)    21(1)      15(1)      11(1)      -1(1)       2(1)      -3(1)
C(22)    18(1)      23(2)      22(1)       0(1)       1(1)      -3(1)
C(23)    26(2)      30(2)      26(2)       7(1)       8(1)       1(1)
C(24)    33(2)      21(2)      39(2)      -1(1)      16(2)       2(1)
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic
         displacement parameters (A^2 x 10^3) for 16.
         ________________________________________________________________
                         x             y             z           U(eq)
         ________________________________________________________________
          H(1A)        3372          3472          3534          19
          H(2A)        4338          4607          4138          19
          H(3A)        5238          5042          3624          24
          H(4A)        1775         -1583          1340          20
          H(5A)         803          -429           781          20
          H(6A)         -99           -43          1379          22
          H(1B)        3481          -949          4445          22
          H(2B)        2489         -2094          4258          23
          H(4B)        1624          1238          2676          25
          H(5B)        2615          2408          2887          23
          H(8A)        4321          -131          4289          19
          H(8B)        4550          1223          4966          19
          H(10A)       6082          4102          3020          30
          H(10B)       6017          2657          3588          30
          H(11A)       6392          4145          5043          32
          H(12A)       7101          5011          3750          52
          H(12B)       7303          5211          4907          52
          H(13A)       1623         -5952           350          22
          H(14A)       2594         -7186           532          24
          H(16A)       3500         -3999          2215          22
          H(17A)       2541         -2721          1987          22
          H(20A)        812         -5171           587          21
          H(20B)        570         -3809           -75          21
          H(22A)       -824         -1942          1941          26
          H(22B)       -971         -2193           819          26
          H(23A)      -1302           381           678          32
          H(24A)      -1689          -711          2253          36
          H(24B)      -1983           714          1634          36
                      ____________________________________________________________________________
